jying96 personal page - To The Moon

jying96

No personal profile

1Follow

0Followers

0Topic

0Badge

2021-06-25

Never ending of sales

Southeast Asia’s Attempts at Replicating Singles’ Day Sales Drive Shopping Boom

2021-06-24

Great!

Why I Believe NIO Will Beat Out Tesla

2021-06-23

Great

Got $1,000? Buy These Hot Growth Stocks Before They Take Off

2021-06-22

Nice!

Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week

2021-06-19

Great!

PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today

2021-06-19

Nice!

Adobe Getting Lift From Economic Reopening Post-Pandemic

2021-06-18

Oh no…

AstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand

2021-06-18

Challenging

Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider

2021-06-18

Good news!

Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3578295543603682,"uuid":"3578295543603682","gmtCreate":1615201519579,"gmtModify":1615201519579,"name":"jying96","pinyin":"jying96","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":126856071,"gmtCreate":1624552429193,"gmtModify":1703840297325,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Never ending of sales&nbsp;","listText":"Never ending of sales&nbsp;","text":"Never ending of sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126856071","repostId":"1120836318","repostType":4,"repost":{"id":"1120836318","pubTimestamp":1624545855,"share":"https://ttm.financial/m/news/1120836318?lang=&edition=fundamental","pubTime":"2021-06-24 22:44","market":"us","language":"en","title":"Southeast Asia’s Attempts at Replicating Singles’ Day Sales Drive Shopping Boom","url":"https://stock-news.laohu8.com/highlight/detail?id=1120836318","media":"Bloomberg","summary":"Sea Ltd rose over 5% in morning trading Thursday.\n\n(Bloomberg) -- Monthly mega-sales events are emer","content":"<p><img src=\"https://static.tigerbbs.com/aa7a5c57d1b1b99cf909292dac1b2558\" tg-width=\"960\" tg-height=\"625\"></p>\n<p><a href=\"https://laohu8.com/S/SE\">Sea Ltd</a> rose over 5% in morning trading&nbsp;Thursday.</p>\n<p><img src=\"https://static.tigerbbs.com/67d3a0d876a9b7237bb2aee7a671d4f8\" tg-width=\"603\" tg-height=\"499\"></p>\n<p>(Bloomberg) -- Monthly mega-sales events are emerging as a key driver for Southeast Asia’s online-shopping boom, a study showed, as the region’s retailers are seeking to duplicate the success of China’s Singles Day and North America’s Black Friday.</p>\n<p>About 86% of the roughly 4,000 people surveyed in Southeast Asia said they bought products online during sales days pegged to identical-number dates such as 6/6 and 7/7, according to the study by Facebook Inc. and Bain &amp; Co. Of these buyers, 43% were first-time online shoppers, with the highest percentage of them in Thailand and Vietnam.</p>\n<p>Alibaba Group Holding Ltd.’s Lazada, Sea Ltd.’s Shopee and Qoo10 are trying to lure online shoppers by offering huge bargains and special deals in the region of more than 650 million people. Since the outbreak of Covid-19, a growing number of retailers and brands have piggybacked on the e-commerce giants’ marketing to capture a bigger share of online sales.</p>\n<p>“Mega-sales days are something that uniquely started happening within Southeast Asia,” Benjamin Joe, vice president of Southeast Asia and emerging markets at Facebook, said during a virtual briefing on Wednesday. “Historically, it was a discount-driven, one-day event, but what we’re seeing is a repeat of numbers like 7/7, a pattern,” with apps offering rewards and gamification to attract buyers, he added.</p>\n<p>About 72% of the surveyed said they plan their mega-sales purchases ahead of the events. About 63% used social media to discover new products and a majority of those said they did so via video.</p>\n<p>Facebook’s Instagram Adds Shopping Via Images, Virtual Try-On</p>\n<p>The report used data from GlobalWebIndex Core Survey Panel involving about 4,000 internet users across Indonesia, Malaysia, the Philippines, Thailand and Vietnam in the fourth quarter of 2020.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Southeast Asia’s Attempts at Replicating Singles’ Day Sales Drive Shopping Boom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoutheast Asia’s Attempts at Replicating Singles’ Day Sales Drive Shopping Boom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/southeast-asia-attempts-replicating-singles-082630590.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sea Ltd rose over 5% in morning trading Thursday.\n\n(Bloomberg) -- Monthly mega-sales events are emerging as a key driver for Southeast Asia’s online-shopping boom, a study showed, as the region’s ...</p>\n\n<a href=\"https://finance.yahoo.com/news/southeast-asia-attempts-replicating-singles-082630590.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://finance.yahoo.com/news/southeast-asia-attempts-replicating-singles-082630590.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120836318","content_text":"Sea Ltd rose over 5% in morning trading Thursday.\n\n(Bloomberg) -- Monthly mega-sales events are emerging as a key driver for Southeast Asia’s online-shopping boom, a study showed, as the region’s retailers are seeking to duplicate the success of China’s Singles Day and North America’s Black Friday.\nAbout 86% of the roughly 4,000 people surveyed in Southeast Asia said they bought products online during sales days pegged to identical-number dates such as 6/6 and 7/7, according to the study by Facebook Inc. and Bain & Co. Of these buyers, 43% were first-time online shoppers, with the highest percentage of them in Thailand and Vietnam.\nAlibaba Group Holding Ltd.’s Lazada, Sea Ltd.’s Shopee and Qoo10 are trying to lure online shoppers by offering huge bargains and special deals in the region of more than 650 million people. Since the outbreak of Covid-19, a growing number of retailers and brands have piggybacked on the e-commerce giants’ marketing to capture a bigger share of online sales.\n“Mega-sales days are something that uniquely started happening within Southeast Asia,” Benjamin Joe, vice president of Southeast Asia and emerging markets at Facebook, said during a virtual briefing on Wednesday. “Historically, it was a discount-driven, one-day event, but what we’re seeing is a repeat of numbers like 7/7, a pattern,” with apps offering rewards and gamification to attract buyers, he added.\nAbout 72% of the surveyed said they plan their mega-sales purchases ahead of the events. About 63% used social media to discover new products and a majority of those said they did so via video.\nFacebook’s Instagram Adds Shopping Via Images, Virtual Try-On\nThe report used data from GlobalWebIndex Core Survey Panel involving about 4,000 internet users across Indonesia, Malaysia, the Philippines, Thailand and Vietnam in the fourth quarter of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121284124,"gmtCreate":1624465646268,"gmtModify":1703837707980,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121284124","repostId":"1145825451","repostType":4,"repost":{"id":"1145825451","pubTimestamp":1624433586,"share":"https://ttm.financial/m/news/1145825451?lang=&edition=fundamental","pubTime":"2021-06-23 15:33","market":"us","language":"en","title":"Why I Believe NIO Will Beat Out Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=1145825451","media":"InvestorPlace","summary":"The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.Super fans of the latest and greatest high-endTesla, Inc. model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.The go","content":"<blockquote>\n <b>The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.</b>\n</blockquote>\n<p>Super fans of the latest and greatest high-end<b>Tesla, Inc.</b>(NASDAQ:<b>TSLA</b>) model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.</p>\n<p><img src=\"https://static.tigerbbs.com/b294a3604c7ba82bd19b3c70be3a4020\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: nrqemi / Shutterstock.com</p>\n<p>Musk wrote there was… “No need, as Plaid is just so good.”</p>\n<p>The Model S Plaid Plus was supposed to be the fastest, most powerful and priciest version of the company’s Model S. Priced at $149,990, it was to feature a range of 520 miles, thanks to its innovative 4680 battery cells, 1,100 horsepower and the ability to speed from 0 to 60 mph in less than two seconds.</p>\n<p>Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.</p>\n<p>As a way to “sugar coat” its flip flop, Tesla said the Model S Plaid is just as fast as the Model S Plaid Plus and $20,000 cheaper. Humm.</p>\n<p>This “bait and switch” has some Tesla fans worried, since they had deposits on the Model S Plaid Plus and wanted the innovative 4680 battery cells that Tesla had been touting as the key to longer range and more power. Essentially, the 4680 battery cells were the latest great Tesla development, since they were the first batteries to also be a structural component that supposedly allowed Tesla to lower the weight of its vehicles.</p>\n<p>Both the company’s Austin and Berlin manufacturing plants now under construction are supposed to also be making the 4680 batteries for new Tesla vehicles. If there is a problem with the engineering associated with utilizing the 4680 batteries or making them a structural component, then Tesla has grossly miscalculated, which is now worrying investors.</p>\n<p>Clearly something happened to delay the 4680 batteries that were supposed to provide Tesla with a competitive and engineering edge. For Tesla’s sake, I hope they figure out the problems associated with their much hyped 4680 battery cells, otherwise concerns about its two new manufacturing plants will emerge, as well as the stock losing more of its “mojo.”</p>\n<p>As someone who owns more than a few high-performance vehicles, I can tell you that the engineering geeks I know do<i>not</i>want to get a new Model S Plaid instead of a Model S Plaid Plus and will likely ask for their deposits back.</p>\n<p>What Tesla did is like Ferrari or Porsche telling its customers that one of their much-hyped new performance models is now not being sold because the base model was just as good! Car fanatics, like myself, like the latest and greatest engineering tidbits, so we would rather cancel our orders versus settle for a base model.</p>\n<p>The good news for Tesla is that its China sales in May resurged to 21,936, up sharply from 11,671 in April. The company’s sales tend to spike at the end of each quarter. For example, Tesla sold 35,478 vehicles in China in March, which was the strongest month ever in China.</p>\n<p>This is raising expectations for very strong China sales in June, especially now that the Model Y is being manufactured in Shanghai. Interestingly, since most Chinese Teslas are now made with iron phosphate batteries, these vehicles have lower range than its lithium cobalt vehicles, but its iron phosphate vehicles are cheaper and now increasingly being exported to Europe.</p>\n<p>However, I’m convinced another electric vehicle (EV) company will eventually displace Tesla as the biggest manufacturer of EVs in China.</p>\n<p><b>Taking Advantage of the EV Revolution’s Profit Potential</b></p>\n<p>I’m talking about&nbsp;<b>Nio, Inc.</b>(NYSE:<b>NIO</b>). The reality is that this company is on the verge of dominating the EV market in China and Hong Kong. It’s why I put NIO on my<b><i>Platinum Growth Club</i></b>Model Portfolio back in February.</p>\n<p>The company boasts that it is the “next-generation car company,” as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence (AI). NIO currently offers an electric seven-seater SUV (ES8) and a five-seater electric SUV (ES6) and recently introduced an attractive electric sedan (ET7). Its vehicles utilize NOMI, an in-vehicle artificial intelligence assistant.</p>\n<p>The company is also partnering with cutting-edge chip companies like<b>NVIDIA Corporation</b>(NASDAQ:<b>NVDA</b>), another one of my<b><i>Platinum Growth Club</i></b>Model Portfolio stocks. NIO plans to use the NVIDIA DRIVE Orin system-on-a-chip for its electric vehicles that will provide autonomous driving capabilities. The NVIDIA DRIVE Orin-powered supercomputer, which is being called Adam, will be launched in the ET7 sedan in China in 2022. Announcements like this are very positive, so NIO has been stealing some of Tesla’s thunder lately.</p>\n<p>Now, it’s important to note that NIO was bailed out by the Chinese government. Last year, the Chinese government injected $1 billion and now has a 24% ownership in the company. The reality is that China wants to dominate at least five major industries by 2025, and NIO is now its ticket to dominate EV manufacturing.</p>\n<p>With the backing of the Chinese government, some Wall Street firms are eager to help NIO by issuing new debt or equity. So, I wouldn’t be surprised if NIO surpasses Tesla, which is currently number-two in China, for market share in the upcoming years.</p>\n<p>That means, if you missed Tesla’s parabolic run like I did, NIO is essentially giving us a “second chance” to make money in a potentially explosive electric vehicle company.</p>\n<p>Shares of NIO climbed nearly 13% since the company’s June 4 announcement of its May delivery report and positive analyst comments, while Tesla shares rose almost 3%. First, NIO revealed that the global chip shortage is starting to take a toll on its business. NIO only delivered 6,711 vehicles in May, or a 5.5% decline from April’s deliveries. Company management noted that deliveries were “adversely impacted for several days due to the volatility of semiconductor supply and certain logistical adjustments.”</p>\n<p>Interestingly, despite the month-to-month dip, NIO’s deliveries were still up 95.3% year-over-year. Strong demand in China even inspired a Citigroup analyst to upgrade NIO to a buy rating, as he expects demand to accelerate in the coming months.</p>\n<p>In other words, NIO represents the<b>crème de la crème</b>of EV stocks right now.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why I Believe NIO Will Beat Out Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy I Believe NIO Will Beat Out Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 15:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.\n\nSuper fans of the latest and greatest high-endTesla, Inc.(NASDAQ:TSLA) model received some disappointing news a week ...</p>\n\n<a href=\"https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145825451","content_text":"The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.\n\nSuper fans of the latest and greatest high-endTesla, Inc.(NASDAQ:TSLA) model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.\nSource: nrqemi / Shutterstock.com\nMusk wrote there was… “No need, as Plaid is just so good.”\nThe Model S Plaid Plus was supposed to be the fastest, most powerful and priciest version of the company’s Model S. Priced at $149,990, it was to feature a range of 520 miles, thanks to its innovative 4680 battery cells, 1,100 horsepower and the ability to speed from 0 to 60 mph in less than two seconds.\nInstead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.\nAs a way to “sugar coat” its flip flop, Tesla said the Model S Plaid is just as fast as the Model S Plaid Plus and $20,000 cheaper. Humm.\nThis “bait and switch” has some Tesla fans worried, since they had deposits on the Model S Plaid Plus and wanted the innovative 4680 battery cells that Tesla had been touting as the key to longer range and more power. Essentially, the 4680 battery cells were the latest great Tesla development, since they were the first batteries to also be a structural component that supposedly allowed Tesla to lower the weight of its vehicles.\nBoth the company’s Austin and Berlin manufacturing plants now under construction are supposed to also be making the 4680 batteries for new Tesla vehicles. If there is a problem with the engineering associated with utilizing the 4680 batteries or making them a structural component, then Tesla has grossly miscalculated, which is now worrying investors.\nClearly something happened to delay the 4680 batteries that were supposed to provide Tesla with a competitive and engineering edge. For Tesla’s sake, I hope they figure out the problems associated with their much hyped 4680 battery cells, otherwise concerns about its two new manufacturing plants will emerge, as well as the stock losing more of its “mojo.”\nAs someone who owns more than a few high-performance vehicles, I can tell you that the engineering geeks I know donotwant to get a new Model S Plaid instead of a Model S Plaid Plus and will likely ask for their deposits back.\nWhat Tesla did is like Ferrari or Porsche telling its customers that one of their much-hyped new performance models is now not being sold because the base model was just as good! Car fanatics, like myself, like the latest and greatest engineering tidbits, so we would rather cancel our orders versus settle for a base model.\nThe good news for Tesla is that its China sales in May resurged to 21,936, up sharply from 11,671 in April. The company’s sales tend to spike at the end of each quarter. For example, Tesla sold 35,478 vehicles in China in March, which was the strongest month ever in China.\nThis is raising expectations for very strong China sales in June, especially now that the Model Y is being manufactured in Shanghai. Interestingly, since most Chinese Teslas are now made with iron phosphate batteries, these vehicles have lower range than its lithium cobalt vehicles, but its iron phosphate vehicles are cheaper and now increasingly being exported to Europe.\nHowever, I’m convinced another electric vehicle (EV) company will eventually displace Tesla as the biggest manufacturer of EVs in China.\nTaking Advantage of the EV Revolution’s Profit Potential\nI’m talking about Nio, Inc.(NYSE:NIO). The reality is that this company is on the verge of dominating the EV market in China and Hong Kong. It’s why I put NIO on myPlatinum Growth ClubModel Portfolio back in February.\nThe company boasts that it is the “next-generation car company,” as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence (AI). NIO currently offers an electric seven-seater SUV (ES8) and a five-seater electric SUV (ES6) and recently introduced an attractive electric sedan (ET7). Its vehicles utilize NOMI, an in-vehicle artificial intelligence assistant.\nThe company is also partnering with cutting-edge chip companies likeNVIDIA Corporation(NASDAQ:NVDA), another one of myPlatinum Growth ClubModel Portfolio stocks. NIO plans to use the NVIDIA DRIVE Orin system-on-a-chip for its electric vehicles that will provide autonomous driving capabilities. The NVIDIA DRIVE Orin-powered supercomputer, which is being called Adam, will be launched in the ET7 sedan in China in 2022. Announcements like this are very positive, so NIO has been stealing some of Tesla’s thunder lately.\nNow, it’s important to note that NIO was bailed out by the Chinese government. Last year, the Chinese government injected $1 billion and now has a 24% ownership in the company. The reality is that China wants to dominate at least five major industries by 2025, and NIO is now its ticket to dominate EV manufacturing.\nWith the backing of the Chinese government, some Wall Street firms are eager to help NIO by issuing new debt or equity. So, I wouldn’t be surprised if NIO surpasses Tesla, which is currently number-two in China, for market share in the upcoming years.\nThat means, if you missed Tesla’s parabolic run like I did, NIO is essentially giving us a “second chance” to make money in a potentially explosive electric vehicle company.\nShares of NIO climbed nearly 13% since the company’s June 4 announcement of its May delivery report and positive analyst comments, while Tesla shares rose almost 3%. First, NIO revealed that the global chip shortage is starting to take a toll on its business. NIO only delivered 6,711 vehicles in May, or a 5.5% decline from April’s deliveries. Company management noted that deliveries were “adversely impacted for several days due to the volatility of semiconductor supply and certain logistical adjustments.”\nInterestingly, despite the month-to-month dip, NIO’s deliveries were still up 95.3% year-over-year. Strong demand in China even inspired a Citigroup analyst to upgrade NIO to a buy rating, as he expects demand to accelerate in the coming months.\nIn other words, NIO represents thecrème de la crèmeof EV stocks right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123850779,"gmtCreate":1624417021291,"gmtModify":1703836042030,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123850779","repostId":"1125623159","repostType":4,"repost":{"id":"1125623159","pubTimestamp":1624416292,"share":"https://ttm.financial/m/news/1125623159?lang=&edition=fundamental","pubTime":"2021-06-23 10:44","market":"us","language":"en","title":"Got $1,000? Buy These Hot Growth Stocks Before They Take Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1125623159","media":"fool","summary":"The first half of the year hasn't been great for the likes of Cirrus Logic(NASDAQ:CRUS) and Advanced","content":"<p>The first half of the year hasn't been great for the likes of&nbsp;<b>Cirrus Logic</b>(NASDAQ:CRUS)&nbsp;and&nbsp;<b>Advanced Micro Devices</b>(NASDAQ:AMD). Share prices of both companies have headed south so far in 2021.</p>\n<p>But that may not be the case forever as Cirrus Logic and AMD are sitting on a bunch of terrific growth drivers that could turn their stock price fortunes around in the second half of the year.</p>\n<p>Let's look at the reasons why investors might be wise to put down $1,000 on these two stocks right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a4bfea08060592f98ee04ba258f5c724\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>AAPLDATA BY YCHARTS</span></p>\n<p>1. Cirrus Logic</p>\n<p>It is no secret that&nbsp;<b>Apple</b>'s(NASDAQ:AAPL)5G-enabled iPhone 12 models have beena huge hitamong customers, sending the smartphone giant's revenue and earnings north ina spectacular manner. Cirrus Logic hasreaped the benefitsof the same as Apple is the chipmaker's largest source of revenue, accounting for 76%&nbsp;of the top line last quarter. The iPhone maker had produced 83% of Cirrus' total revenue in fiscal 2021 that ended in March.</p>\n<p>Not surprisingly, Cirrus' top and bottom lines stepped on the gas in the second half of 2020 after showing signs of plateauing earlier last year. The company delivered $780 million&nbsp;in revenue in the second half of fiscal 2021 that ended in March this year, up 19% year over year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9fae0db2babaa80985a84ec5d66b3fb9\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>CRUS REVENUE (TTM)DATA BY YCHARTS</span></p>\n<p>However, Cirrus investors were in for a scare after the company's guidance for the first quarter of fiscal 2022, which ends this month,failed to meet expectations. The chipmaker blamed supply chain issues for its failure to meet expectations as it was unable to meet the robust end-market demand. Additionally, Apple may have rolled back orders for the iPhone 12 series as the supply chain is already in motion&nbsp;to roll out this year's models.</p>\n<p>However, Cirrus did provide a hint that its business will pick up the pace in the second half of the year. CEO John Forsyth said on the Aprilearnings conference call:</p>\n<blockquote>\n In the coming months, we will begin shipping new technologies to our customers across a range of end devices, including important new content in the high-performance mixed-signal category. And based on these factors, we expect to accelerate revenue growth in FY 2022.\n</blockquote>\n<p>Cirrus' confidence isn't misplaced as its largest customer is expected to witness a big boom in sales. Reports suggest that Apple's suppliers have already started making components&nbsp;for this year's iPhones. What's more, the company is expected to bump its initial production of the 2021 iPhone lineup by 25% to 100 million&nbsp;units as compared to the iPhone 12's initial order size of 80 million units, according to Dan Ives of Wedbush. He also adds that Apple could finish 2021 with nearly 250 million units in sales, which would be its highest since 231 million sold in 2015.</p>\n<p>The iPhone's terrific momentum is expected to continue in 2022. Juniper Research estimates&nbsp;that Apple could sell $200 billion worth of iPhones next year, which doesn't look like a very ambitious target as the company has generated&nbsp;over $113 billion in iPhone revenue over the past six months.</p>\n<p>These tailwinds should help Cirrus shares break out from their mediocrity and set the market on fire in the future. So, investors looking to add agrowth stockto their portfolio should seriously consider Cirrus Logic as it trades at an attractive forward earnings multiple&nbsp;of just 15.</p>\n<p>2. AMD</p>\n<p>It is startling to see AMD stock taking a beating in 2021 considering the pace at which the chipmaker has been growing. The companydelivered outstanding resultsin 2020 and it has continued in the same vein in 2021, with revenue increasing a whopping 93% in the first quarter to $3.45 billion.</p>\n<p>AMD aims to clock 50% revenue growth this year, which would be better than its 2020 revenue increase of 45%. However, AMD can exceed its own expectations. The company had given investors a glimpse of the same when it reported its first-quarter results in April and raised its full-year revenue guidance. It was originally anticipating&nbsp;a 37% year-over-year increase in 2021 revenue, but a robust demand environment has encouraged AMD to raise guidance substantially.</p>\n<p>There are three reasons why AMD can turn in better-than-expected results: a short supply of graphics cards leading to a sharp spike in prices, market share gains against<b>Intel</b>(NASDAQ:INTC)in the server and PC processor markets, and the rapidly growing sales of the latest gaming consoles.</p>\n<p>AMD's computing and graphics segment, which recorded 46% year-over-year revenue growth in the first quarter to $2.1 billion and accounted for nearly 61% of the total revenue, is poised to benefit from two of those tailwinds. According to AMD, a mix of higher sales volumes and stronger average selling prices (ASPs) of the Ryzen CPU (central processing unit) and Radeon GPU (graphics processing unit) products drove the segment's impressive growth.</p>\n<p>For instance, sales of AMD's Radeon 6000 series high-end GPUs doubled&nbsp;quarter over quarter. AMD says that this is just the beginning as the Radeon 6000 seriessales could\"grow significantly over the coming quarters as we ramp production,\" indicating that the company is trying to address the problem of short supply. Even better, the GPU market is poised for long-term growth. Jon Peddie Research forecasts&nbsp;sales of discrete graphics cards to hit $54 billion in 2025 from $23.6 billion last year.</p>\n<p>AMD is one of the two major players in this space, holding a market share of nearly&nbsp;20%. It is trying to make a bigger dent in the market with new technologies, so don't be surprised to see it win big from GPUs in the future. Meanwhile, AMD's improving market share in the PC processor market thanks to the success of its Ryzen CPUs is turning out to be another catalyst.</p>\n<p>According to a survey carried out by popular video game distribution service Steam, AMD now has just over&nbsp;30% of the CPU market under its control, with Intel commanding the rest. It is worth noting that AMD's market share was less than 20% in 2017. But AMD'stechnological advantageover Intel has helped it take away share from its bigger rival. The trend may not change anytime soon thanks to AMD'ssuperior manufacturing process.</p>\n<p>Finally, AMD's enterprise, embedded, and semi-custom (EESC) business is riding on two solid catalysts. One of them is AMD's market share gains against Intel in the server market. AMD's superior manufacturing process has allowed it to increase its market share to nearly 9% at the end of the first quarter of 2021 from almost nothing at the end of 2017, according&nbsp;to Mercury Research.</p>\n<p>AMD investors can expect the company totake more market shareaway from Intel in the server space thanks to the former's Milan processors that are reportedly more powerful&nbsp;than Chipzilla's offerings. Throw in the terrific momentum of the new console cycle that has given AMD abig shot in the arm, and investors have another solid reason to buy thistop tech stockthat is trading&nbsp;at just 34 times trailing earnings as compared to the five-year average multiple of 124.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These Hot Growth Stocks Before They Take Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These Hot Growth Stocks Before They Take Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 10:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/got-1000-buy-hot-growth-stocks-before-take-off/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The first half of the year hasn't been great for the likes of Cirrus Logic(NASDAQ:CRUS) and Advanced Micro Devices(NASDAQ:AMD). Share prices of both companies have headed south so far in 2021.\nBut ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/got-1000-buy-hot-growth-stocks-before-take-off/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRUS":"凌云半导体","AMD":"美国超微公司"},"source_url":"https://www.fool.com/investing/2021/06/22/got-1000-buy-hot-growth-stocks-before-take-off/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125623159","content_text":"The first half of the year hasn't been great for the likes of Cirrus Logic(NASDAQ:CRUS) and Advanced Micro Devices(NASDAQ:AMD). Share prices of both companies have headed south so far in 2021.\nBut that may not be the case forever as Cirrus Logic and AMD are sitting on a bunch of terrific growth drivers that could turn their stock price fortunes around in the second half of the year.\nLet's look at the reasons why investors might be wise to put down $1,000 on these two stocks right now.\nAAPLDATA BY YCHARTS\n1. Cirrus Logic\nIt is no secret that Apple's(NASDAQ:AAPL)5G-enabled iPhone 12 models have beena huge hitamong customers, sending the smartphone giant's revenue and earnings north ina spectacular manner. Cirrus Logic hasreaped the benefitsof the same as Apple is the chipmaker's largest source of revenue, accounting for 76% of the top line last quarter. The iPhone maker had produced 83% of Cirrus' total revenue in fiscal 2021 that ended in March.\nNot surprisingly, Cirrus' top and bottom lines stepped on the gas in the second half of 2020 after showing signs of plateauing earlier last year. The company delivered $780 million in revenue in the second half of fiscal 2021 that ended in March this year, up 19% year over year.\nCRUS REVENUE (TTM)DATA BY YCHARTS\nHowever, Cirrus investors were in for a scare after the company's guidance for the first quarter of fiscal 2022, which ends this month,failed to meet expectations. The chipmaker blamed supply chain issues for its failure to meet expectations as it was unable to meet the robust end-market demand. Additionally, Apple may have rolled back orders for the iPhone 12 series as the supply chain is already in motion to roll out this year's models.\nHowever, Cirrus did provide a hint that its business will pick up the pace in the second half of the year. CEO John Forsyth said on the Aprilearnings conference call:\n\n In the coming months, we will begin shipping new technologies to our customers across a range of end devices, including important new content in the high-performance mixed-signal category. And based on these factors, we expect to accelerate revenue growth in FY 2022.\n\nCirrus' confidence isn't misplaced as its largest customer is expected to witness a big boom in sales. Reports suggest that Apple's suppliers have already started making components for this year's iPhones. What's more, the company is expected to bump its initial production of the 2021 iPhone lineup by 25% to 100 million units as compared to the iPhone 12's initial order size of 80 million units, according to Dan Ives of Wedbush. He also adds that Apple could finish 2021 with nearly 250 million units in sales, which would be its highest since 231 million sold in 2015.\nThe iPhone's terrific momentum is expected to continue in 2022. Juniper Research estimates that Apple could sell $200 billion worth of iPhones next year, which doesn't look like a very ambitious target as the company has generated over $113 billion in iPhone revenue over the past six months.\nThese tailwinds should help Cirrus shares break out from their mediocrity and set the market on fire in the future. So, investors looking to add agrowth stockto their portfolio should seriously consider Cirrus Logic as it trades at an attractive forward earnings multiple of just 15.\n2. AMD\nIt is startling to see AMD stock taking a beating in 2021 considering the pace at which the chipmaker has been growing. The companydelivered outstanding resultsin 2020 and it has continued in the same vein in 2021, with revenue increasing a whopping 93% in the first quarter to $3.45 billion.\nAMD aims to clock 50% revenue growth this year, which would be better than its 2020 revenue increase of 45%. However, AMD can exceed its own expectations. The company had given investors a glimpse of the same when it reported its first-quarter results in April and raised its full-year revenue guidance. It was originally anticipating a 37% year-over-year increase in 2021 revenue, but a robust demand environment has encouraged AMD to raise guidance substantially.\nThere are three reasons why AMD can turn in better-than-expected results: a short supply of graphics cards leading to a sharp spike in prices, market share gains againstIntel(NASDAQ:INTC)in the server and PC processor markets, and the rapidly growing sales of the latest gaming consoles.\nAMD's computing and graphics segment, which recorded 46% year-over-year revenue growth in the first quarter to $2.1 billion and accounted for nearly 61% of the total revenue, is poised to benefit from two of those tailwinds. According to AMD, a mix of higher sales volumes and stronger average selling prices (ASPs) of the Ryzen CPU (central processing unit) and Radeon GPU (graphics processing unit) products drove the segment's impressive growth.\nFor instance, sales of AMD's Radeon 6000 series high-end GPUs doubled quarter over quarter. AMD says that this is just the beginning as the Radeon 6000 seriessales could\"grow significantly over the coming quarters as we ramp production,\" indicating that the company is trying to address the problem of short supply. Even better, the GPU market is poised for long-term growth. Jon Peddie Research forecasts sales of discrete graphics cards to hit $54 billion in 2025 from $23.6 billion last year.\nAMD is one of the two major players in this space, holding a market share of nearly 20%. It is trying to make a bigger dent in the market with new technologies, so don't be surprised to see it win big from GPUs in the future. Meanwhile, AMD's improving market share in the PC processor market thanks to the success of its Ryzen CPUs is turning out to be another catalyst.\nAccording to a survey carried out by popular video game distribution service Steam, AMD now has just over 30% of the CPU market under its control, with Intel commanding the rest. It is worth noting that AMD's market share was less than 20% in 2017. But AMD'stechnological advantageover Intel has helped it take away share from its bigger rival. The trend may not change anytime soon thanks to AMD'ssuperior manufacturing process.\nFinally, AMD's enterprise, embedded, and semi-custom (EESC) business is riding on two solid catalysts. One of them is AMD's market share gains against Intel in the server market. AMD's superior manufacturing process has allowed it to increase its market share to nearly 9% at the end of the first quarter of 2021 from almost nothing at the end of 2017, according to Mercury Research.\nAMD investors can expect the company totake more market shareaway from Intel in the server space thanks to the former's Milan processors that are reportedly more powerful than Chipzilla's offerings. Throw in the terrific momentum of the new console cycle that has given AMD abig shot in the arm, and investors have another solid reason to buy thistop tech stockthat is trading at just 34 times trailing earnings as compared to the five-year average multiple of 124.","news_type":1},"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120941724,"gmtCreate":1624293588368,"gmtModify":1703832819024,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Nice!&nbsp;","listText":"Nice!&nbsp;","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120941724","repostId":"1154249454","repostType":4,"repost":{"id":"1154249454","pubTimestamp":1624230573,"share":"https://ttm.financial/m/news/1154249454?lang=&edition=fundamental","pubTime":"2021-06-21 07:09","market":"us","language":"en","title":"Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1154249454","media":"barrons","summary":"A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. Wednesday will also feature analyst days and investor events from Johnson & Johnson, GlaxoSmithKline,and Equinix.Economic data out this week include IHS’ Manufacturing and Services Purchasing Managers’ Indexes for June on Wednesday. Both are expected to hold near their record highs. The Census Bureau will r","content":"<p>A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. Wednesday will also feature analyst days and investor events from&nbsp;Johnson &amp;&nbsp;Johnson,&nbsp;GlaxoSmithKline,and&nbsp;Equinix.</p>\n<p>Economic data out this week include IHS’ Manufacturing and Services Purchasing Managers’ Indexes for June on Wednesday. Both are expected to hold near their record highs. The Census Bureau will release the durable-goods report for May on Thursday. Orders—often seen as a decent proxy for business investment—are expected to rise 3.3% month over month.</p>\n<p>And on Friday, the Bureau of Economic Analysis will report personal income and consumption for May. Spending is forecast to continue rising despite a drop off in income as stimulus checks finished being sent out in April.</p>\n<p>Monday 6/21</p>\n<p><b>The Federal Reserve Bank</b>of Chicago releases its National Activity index, a gauge of overall economic activity, for May. Expectations are for a 0.50 reading, higher than April’s 0.24 figure. A positive reading indicates economic growth that is above historical trends.</p>\n<p>Tuesday 6/22</p>\n<p><b>The National Association</b>of Realtors reports existing-home sales for May. Economists forecast a seasonally adjusted annual rate of 5.7 million homes sold, about 150,000 fewer than the April data. Existing-home sales have fallen for three consecutive months, as supply hasn’t been able to keep up with demand.</p>\n<p>Wednesday 6/23</p>\n<p>Equinix hosts its 2021 analyst day, when the company will update its long-term financial outlook.</p>\n<p>GlaxoSmithKline hosts a conference call, featuring its CEO, Emma Walmsley, to update investors on the company’s strategy for growth and shareholder value creation.</p>\n<p>Johnson &amp; Johnson hosts a webcast to discuss its ESG strategy.</p>\n<p><b>The Census Bureau</b>reports new residential construction data for May. Consensus estimate is for a seasonally adjusted annual rate of 875,000 new single-family homes sold, slightly higher than April’s 863,000. Similar to existing-home sales, new-home sales have fallen from their recent peak of 993,000 in January of this year.</p>\n<p><b>IHS Markitreports</b>both its Manufacturing and Services Purchasing Managers’ indexes for June. Expectations are for a 61.5 reading for the Manufacturing PMI, and a 69.8 figure for the Services PMI. Both projections are comparable to the May data as well as being near record highs for their respective indexes.</p>\n<p>Thursday 6/24</p>\n<p><b>The Bureau of Economic Analysis</b>reports the third and final estimate of first-quarter gross-domestic-product growth. Economists forecast a seasonally adjusted annual growth rate of 6.4%.</p>\n<p>Accenture,Darden Restaurants, FedEx, and Nike hold conference calls to discuss quarterly results.</p>\n<p><b>The Bank of England</b>announces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at 0.1%.</p>\n<p><b>The Census Bureau</b>releases the durable-goods report for May. The consensus call is for new orders of manufactured goods to rise 2.8% month over month to $253 billion. Excluding transportation, new orders are projected at 1%, matching the April data.</p>\n<p>Friday 6/25</p>\n<p>CarMax and Paychex report earnings.</p>\n<p><b>The BEA reports</b>personal income and consumption for May. Income is expected to fall 3% month over month, after plummeting 13.1% in April. This reflects a dropoff in stimulus checks that first were sent out in March. Spending is seen rising 0.5%, comparable to the April data.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 07:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/nike-fedex-johnson-johnson-darden-and-other-stocks-for-investors-to-watch-this-week-51624215603?mod=hp_LEAD_3><strong>barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. ...</p>\n\n<a href=\"https://www.barrons.com/articles/nike-fedex-johnson-johnson-darden-and-other-stocks-for-investors-to-watch-this-week-51624215603?mod=hp_LEAD_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","DRI":"达登饭店","FDX":"联邦快递","NKE":"耐克"},"source_url":"https://www.barrons.com/articles/nike-fedex-johnson-johnson-darden-and-other-stocks-for-investors-to-watch-this-week-51624215603?mod=hp_LEAD_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154249454","content_text":"A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. Wednesday will also feature analyst days and investor events from Johnson & Johnson, GlaxoSmithKline,and Equinix.\nEconomic data out this week include IHS’ Manufacturing and Services Purchasing Managers’ Indexes for June on Wednesday. Both are expected to hold near their record highs. The Census Bureau will release the durable-goods report for May on Thursday. Orders—often seen as a decent proxy for business investment—are expected to rise 3.3% month over month.\nAnd on Friday, the Bureau of Economic Analysis will report personal income and consumption for May. Spending is forecast to continue rising despite a drop off in income as stimulus checks finished being sent out in April.\nMonday 6/21\nThe Federal Reserve Bankof Chicago releases its National Activity index, a gauge of overall economic activity, for May. Expectations are for a 0.50 reading, higher than April’s 0.24 figure. A positive reading indicates economic growth that is above historical trends.\nTuesday 6/22\nThe National Associationof Realtors reports existing-home sales for May. Economists forecast a seasonally adjusted annual rate of 5.7 million homes sold, about 150,000 fewer than the April data. Existing-home sales have fallen for three consecutive months, as supply hasn’t been able to keep up with demand.\nWednesday 6/23\nEquinix hosts its 2021 analyst day, when the company will update its long-term financial outlook.\nGlaxoSmithKline hosts a conference call, featuring its CEO, Emma Walmsley, to update investors on the company’s strategy for growth and shareholder value creation.\nJohnson & Johnson hosts a webcast to discuss its ESG strategy.\nThe Census Bureaureports new residential construction data for May. Consensus estimate is for a seasonally adjusted annual rate of 875,000 new single-family homes sold, slightly higher than April’s 863,000. Similar to existing-home sales, new-home sales have fallen from their recent peak of 993,000 in January of this year.\nIHS Markitreportsboth its Manufacturing and Services Purchasing Managers’ indexes for June. Expectations are for a 61.5 reading for the Manufacturing PMI, and a 69.8 figure for the Services PMI. Both projections are comparable to the May data as well as being near record highs for their respective indexes.\nThursday 6/24\nThe Bureau of Economic Analysisreports the third and final estimate of first-quarter gross-domestic-product growth. Economists forecast a seasonally adjusted annual growth rate of 6.4%.\nAccenture,Darden Restaurants, FedEx, and Nike hold conference calls to discuss quarterly results.\nThe Bank of Englandannounces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at 0.1%.\nThe Census Bureaureleases the durable-goods report for May. The consensus call is for new orders of manufactured goods to rise 2.8% month over month to $253 billion. Excluding transportation, new orders are projected at 1%, matching the April data.\nFriday 6/25\nCarMax and Paychex report earnings.\nThe BEA reportspersonal income and consumption for May. Income is expected to fall 3% month over month, after plummeting 13.1% in April. This reflects a dropoff in stimulus checks that first were sent out in March. Spending is seen rising 0.5%, comparable to the April data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162946122,"gmtCreate":1624032709066,"gmtModify":1703827277258,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162946122","repostId":"1192473918","repostType":4,"repost":{"id":"1192473918","pubTimestamp":1624029343,"share":"https://ttm.financial/m/news/1192473918?lang=&edition=fundamental","pubTime":"2021-06-18 23:15","market":"us","language":"en","title":"PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1192473918","media":"investorplace","summary":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Feder","content":"<p><b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).</p>\n<p>The goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.</p>\n<p>According to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.</p>\n<p>Palantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.</p>\n<p>Akash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.</p>\n<blockquote>\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n</blockquote>\n<p>The fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.</p>\n<p>It’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.</p>\n<p>PLTR stock was down 1.1% as of Friday morning.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” ...</p>\n\n<a href=\"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192473918","content_text":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.\nAccording to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.\nPalantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.\nAkash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.\n\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n\nThe fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.\nIt’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.\nPLTR stock was down 1.1% as of Friday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162943055,"gmtCreate":1624032632377,"gmtModify":1703827272399,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162943055","repostId":"2144774740","repostType":4,"repost":{"id":"2144774740","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624030096,"share":"https://ttm.financial/m/news/2144774740?lang=&edition=fundamental","pubTime":"2021-06-18 23:28","market":"us","language":"en","title":"Adobe Getting Lift From Economic Reopening Post-Pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=2144774740","media":"Investors","summary":"Software giant Adobe is benefiting as the economy reopens following the Covid-19 pandemic, a senior executive says.","content":"<p>Software giant <b><a href=\"https://laohu8.com/S/ADBE\">Adobe</a></b> is benefiting as the economy reopens as the Covid-19 pandemic wanes, a senior executive says. The company's beat-and-raise quarterly report provided proof of that. ADBE stock jumped on Friday.</p>\n<p>The maker of digital media and marketing software late Thursday reported fiscal second-quarter earnings that easily topped expectations. Adobe also guided above views for the current quarter.</p>\n<p>The San Jose, Calif.-based company earned an adjusted $3.03 a share on sales of $3.84 billion in the quarter ended June 4. On a year-over-year basis, Adobe earnings rose 24% while sales climbed 23%.</p>\n<p>For the current quarter, Adobe expects to earn an adjusted $3 a share, up 17%, on sales of $3.88 billion, up 20%.</p>\n<h2>ADBE Stock Rises After Earnings Report</h2>\n<p>In morning trading on the stock market today, ADBE stock advanced 2.2%, near 563.35. Earlier in the session, ADBE stock notched a record high 570.</p>\n<p>\"All three of our businesses — Creative Cloud, Document Cloud and <a href=\"https://laohu8.com/S/EXP.AU\">Experience</a> Cloud — just killed it this quarter with excellent performance,\" Chief Financial Officer John Murphy told Investor's Business Daily. \"Content creation and customer experience engagement in personalized ways are resonating across all of our businesses. And it's really driving the momentum and acceleration in the business.\"</p>\n<p>That momentum will continue in the company's seasonally weaker fiscal third quarter, Murphy said. The current quarter includes the summer months of June, July and August.</p>\n<p>\"The macroeconomic stability is giving a lot of enterprises confidence to invest again,\" Murphy said. \"Companies are prioritizing digital transformation.\"</p>\n<p>The reopening of the economy and return to offices after the pandemic should provide a tailwind for Adobe's business, he said.</p>\n<h2>Analysts Raise Price Targets On Adobe Stock</h2>\n<p>At least 15 Wall Street analysts raised their price targets on ADBE stock after the earnings report.</p>\n<p>Mizuho Securities analyst Gregg Moskowitz reiterated his buy rating on ADBE stock and upped his price target to 640 from 600.</p>\n<p>\"Adobe's expansive portfolio of software solutions has made it the gold standard in content creation, consumption, and collaboration,\" Moskowitz said in a note to clients. \"Adobe is very well positioned to benefit from digital transformation with its comprehensive end-to-end offering that differentiates it from competitors.\"</p>\n<p>On June 11, ADBE stock broke out of a 40-week&nbsp;consolidation period&nbsp;at a&nbsp;buy point&nbsp;of 536.98, according to&nbsp;IBD MarketSmith charts.</p>\n<p>However, IBD Leaderboard analysis offered investors an earlier buy point of 525.54 from a cup base within the larger consolidation pattern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adobe Getting Lift From Economic Reopening Post-Pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdobe Getting Lift From Economic Reopening Post-Pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 23:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Software giant <b><a href=\"https://laohu8.com/S/ADBE\">Adobe</a></b> is benefiting as the economy reopens as the Covid-19 pandemic wanes, a senior executive says. The company's beat-and-raise quarterly report provided proof of that. ADBE stock jumped on Friday.</p>\n<p>The maker of digital media and marketing software late Thursday reported fiscal second-quarter earnings that easily topped expectations. Adobe also guided above views for the current quarter.</p>\n<p>The San Jose, Calif.-based company earned an adjusted $3.03 a share on sales of $3.84 billion in the quarter ended June 4. On a year-over-year basis, Adobe earnings rose 24% while sales climbed 23%.</p>\n<p>For the current quarter, Adobe expects to earn an adjusted $3 a share, up 17%, on sales of $3.88 billion, up 20%.</p>\n<h2>ADBE Stock Rises After Earnings Report</h2>\n<p>In morning trading on the stock market today, ADBE stock advanced 2.2%, near 563.35. Earlier in the session, ADBE stock notched a record high 570.</p>\n<p>\"All three of our businesses — Creative Cloud, Document Cloud and <a href=\"https://laohu8.com/S/EXP.AU\">Experience</a> Cloud — just killed it this quarter with excellent performance,\" Chief Financial Officer John Murphy told Investor's Business Daily. \"Content creation and customer experience engagement in personalized ways are resonating across all of our businesses. And it's really driving the momentum and acceleration in the business.\"</p>\n<p>That momentum will continue in the company's seasonally weaker fiscal third quarter, Murphy said. The current quarter includes the summer months of June, July and August.</p>\n<p>\"The macroeconomic stability is giving a lot of enterprises confidence to invest again,\" Murphy said. \"Companies are prioritizing digital transformation.\"</p>\n<p>The reopening of the economy and return to offices after the pandemic should provide a tailwind for Adobe's business, he said.</p>\n<h2>Analysts Raise Price Targets On Adobe Stock</h2>\n<p>At least 15 Wall Street analysts raised their price targets on ADBE stock after the earnings report.</p>\n<p>Mizuho Securities analyst Gregg Moskowitz reiterated his buy rating on ADBE stock and upped his price target to 640 from 600.</p>\n<p>\"Adobe's expansive portfolio of software solutions has made it the gold standard in content creation, consumption, and collaboration,\" Moskowitz said in a note to clients. \"Adobe is very well positioned to benefit from digital transformation with its comprehensive end-to-end offering that differentiates it from competitors.\"</p>\n<p>On June 11, ADBE stock broke out of a 40-week&nbsp;consolidation period&nbsp;at a&nbsp;buy point&nbsp;of 536.98, according to&nbsp;IBD MarketSmith charts.</p>\n<p>However, IBD Leaderboard analysis offered investors an earlier buy point of 525.54 from a cup base within the larger consolidation pattern.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADBE":"Adobe"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144774740","content_text":"Software giant Adobe is benefiting as the economy reopens as the Covid-19 pandemic wanes, a senior executive says. The company's beat-and-raise quarterly report provided proof of that. ADBE stock jumped on Friday.\nThe maker of digital media and marketing software late Thursday reported fiscal second-quarter earnings that easily topped expectations. Adobe also guided above views for the current quarter.\nThe San Jose, Calif.-based company earned an adjusted $3.03 a share on sales of $3.84 billion in the quarter ended June 4. On a year-over-year basis, Adobe earnings rose 24% while sales climbed 23%.\nFor the current quarter, Adobe expects to earn an adjusted $3 a share, up 17%, on sales of $3.88 billion, up 20%.\nADBE Stock Rises After Earnings Report\nIn morning trading on the stock market today, ADBE stock advanced 2.2%, near 563.35. Earlier in the session, ADBE stock notched a record high 570.\n\"All three of our businesses — Creative Cloud, Document Cloud and Experience Cloud — just killed it this quarter with excellent performance,\" Chief Financial Officer John Murphy told Investor's Business Daily. \"Content creation and customer experience engagement in personalized ways are resonating across all of our businesses. And it's really driving the momentum and acceleration in the business.\"\nThat momentum will continue in the company's seasonally weaker fiscal third quarter, Murphy said. The current quarter includes the summer months of June, July and August.\n\"The macroeconomic stability is giving a lot of enterprises confidence to invest again,\" Murphy said. \"Companies are prioritizing digital transformation.\"\nThe reopening of the economy and return to offices after the pandemic should provide a tailwind for Adobe's business, he said.\nAnalysts Raise Price Targets On Adobe Stock\nAt least 15 Wall Street analysts raised their price targets on ADBE stock after the earnings report.\nMizuho Securities analyst Gregg Moskowitz reiterated his buy rating on ADBE stock and upped his price target to 640 from 600.\n\"Adobe's expansive portfolio of software solutions has made it the gold standard in content creation, consumption, and collaboration,\" Moskowitz said in a note to clients. \"Adobe is very well positioned to benefit from digital transformation with its comprehensive end-to-end offering that differentiates it from competitors.\"\nOn June 11, ADBE stock broke out of a 40-week consolidation period at a buy point of 536.98, according to IBD MarketSmith charts.\nHowever, IBD Leaderboard analysis offered investors an earlier buy point of 525.54 from a cup base within the larger consolidation pattern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166530663,"gmtCreate":1624016385152,"gmtModify":1703826618839,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Oh no…","listText":"Oh no…","text":"Oh no…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166530663","repostId":"1176081814","repostType":4,"repost":{"id":"1176081814","pubTimestamp":1624002595,"share":"https://ttm.financial/m/news/1176081814?lang=&edition=fundamental","pubTime":"2021-06-18 15:49","market":"us","language":"en","title":"AstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=1176081814","media":"bloomberg","summary":"AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery tar","content":"<p>AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback for a shot that was meant to be the backbone of the global inoculation effort.</p>\n<p>Thailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only about 3.5 million of those shots this month. Pledging to still give out 6 million doses as planned, officials appear to be making up the shortfall with millions of shots from China’sSinovac Biotech Ltd.</p>\n<p>Shipments of shots made by Siam Bioscience -- AstraZeneca’s Bangkok-based partner, which has links to the Thai royal family -- to Malaysia and the Philippines have also been delayed, though both countries say they don’t expect to be waiting for too long.</p>\n<p>The situation comes on top of delivery problems at India’sSerum Institute of India Ltd., another AstraZeneca partner, which has left developing countries from Nepal to Rwanda short of shots that were promised through the World Health Organization-backed Covax program. Siam Bioscience is AstraZeneca’s sole Covid vaccine partner in Southeast Asia, a region that is trailing on inoculation and where the virus continues to flare, including in Thailand where infections have surged over the past two months.</p>\n<p>AstraZeneca declined to comment, while Siam BioScience didn’t respond to requests for comment.</p>\n<p>The Philippines now expects a batch of nearly 1.2 million AstraZeneca shots to be shipped from Thailand in mid-July rather than this month, though a government official saidthe initial delaywill not derail the country’s vaccination push. In Malaysia, authorities say they’re working to resolve the issues around the delivery schedule, which the government stated in May would see 610,000 doses arrive from Thailand in June and another 410,000 in July.</p>\n<p>AstraZeneca itself is also facing legal action from the European Union for a production shortfall, with the company only delivering 30 million doses to the bloc in the first quarter, compared with an original target of 120 million.</p>\n<p>Seeking Alternatives</p>\n<p>The Anglo-Swedish company, which partnered with the University of Oxford on the vaccine, received orders to supply as many as 3 billion doses worldwide before efficacy data came out last year, more than twice as many as any other first wave shot, data compiled by Bloomberg shows.</p>\n<p>While not exclusive to AstraZeneca, the various delays -- particularly out of India, which has banned the export of Covid vaccines -- have left dozens of countries that were counting on the shot desperate to find doses elsewhere, and undermined the company’s bid to supply the developing world.</p>\n<p>Now, countries are turning to alternatives, particularly shots developed by Chinese companies Sinovac and Sinopharm that recently received approval from the WHO. While they’re less effective than the Messenger RNA vaccines made by Pfizer Inc., BioNTech SE and Moderna Inc., these shots are easier to store and transport.</p>\n<p>Thailand, which aims to vaccinate70% of its populationby the end of this year, is also now allowing regional health authorities to extend the interval between Astrazeneca vaccine doses to 16 weeks, from 10 to 12 weeks previously, though officials say the move is to optimize the shot’s effectiveness and not for lack of supply.</p>\n<p>The country has alsoordered20 million doses of the Pfizer-BioNTech vaccine and isin talksfor 5 million doses of the single-shot Johnson &amp; Johnson vaccine as it continues to expect deliveries of the Astra shots from Siam Bioscience.</p>\n<p>New to Vaccine-making</p>\n<p>AstraZeneca’s vaccine is among the cheapest of the first round of Covid shots because the company said it wouldn’t take a profit, selling it at cost.</p>\n<p>But the lack of economic incentives could have constrained AstraZeneca and its manufacturing partners’ ability to get the supply chain in order, said Carlos Cordon, a professor of strategy and supply chain management at the Institute for Management Development in Lausanne, Switzerland.</p>\n<p>“The supply chain of the Astra vaccine is not an easy one and, logically, one would assume that there will be more than one source of supply to avoid bottlenecks,” Cordon said. “A little bit of an economic incentive would have certainly helped to make companies in the supply chain even eager to make higher production volumes.”</p>\n<p>AstraZeneca’s choice of Thai partner raised questions from the start. Unlike India’s Serum -- which was the world’s biggest vaccine maker before the pandemic -- and other Asia partners like South Korea’sSK Bioscience Co., Siam Bioscience is new to the vaccine-making business.</p>\n<p>The company was founded in 2009 as Thailand’s first domestic bio-pharmaceutical drugmaker by the father of the nation’s current King Maha Vajiralongkorn, to provide cheaper alternatives to imported drugs. It has also made Covid test kits.</p>\n<p>It’s set up by theCrown Property Bureau, an agency that managed assets for the palace no matter who sat on the throne. The company had been operating at a loss in the four years leadingup tothe year of pandemic, when it brought in anet profitof 35.8 million baht ($1.1 million), according to data published by the Department of Business Development.</p>\n<p>In February, Thai Prime Minister Prayuth Chan-Ocha said Siam Bioscience does not seek to profit from making the Astra vaccines.</p>\n<p>Royal Links</p>\n<p>Complicating matters is Thailand’s lese majeste law, which can see jail time ofup to15 years for defaming the royal family. Its sweeping mandate means that little is said publicly about Siam Bioscience, even as concerns over vaccine supplies grow.</p>\n<p>In January, Thai officialssaidthat Siam Bioscience would make 200 million doses each year. They haven’t spoken publicly again about the company in detail since.</p>\n<p>When former prime-ministerial candidate Thanathorn Juangroongruangkit suggested that Siam Bioscience’s royal ties played a role in its appointment as AstraZeneca’s partner, the high-profile government critic waschargedwith royal defamation.</p>\n<p>Prime Minister Prayuthapologizedthis week to the public for the delay, blaming “supply and distribution issues” without elaborating. Neither the Thai government nor Siam Bioscience responded to repeated requests for information on what is causing the supply shortfalls.</p>\n<p>One Thaihealthcareindustry veteran, who asked not to be identified for fear of legal repercussions, likened the situation with Siam Bioscience to a bakery that just started making bread.</p>\n<p>“They still haven’t perfected their craft,” he said. “None of us really knows their production capacity because they haven’t publicized it and we can’t criticize it. No one is willing to say. They can’t say it, because it’s Siam Bioscience.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 15:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-18/astrazeneca-vaccine-faces-more-supply-hurdles-now-from-thailand?srnd=premium-asia><strong>bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-18/astrazeneca-vaccine-faces-more-supply-hurdles-now-from-thailand?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-18/astrazeneca-vaccine-faces-more-supply-hurdles-now-from-thailand?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176081814","content_text":"AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback for a shot that was meant to be the backbone of the global inoculation effort.\nThailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only about 3.5 million of those shots this month. Pledging to still give out 6 million doses as planned, officials appear to be making up the shortfall with millions of shots from China’sSinovac Biotech Ltd.\nShipments of shots made by Siam Bioscience -- AstraZeneca’s Bangkok-based partner, which has links to the Thai royal family -- to Malaysia and the Philippines have also been delayed, though both countries say they don’t expect to be waiting for too long.\nThe situation comes on top of delivery problems at India’sSerum Institute of India Ltd., another AstraZeneca partner, which has left developing countries from Nepal to Rwanda short of shots that were promised through the World Health Organization-backed Covax program. Siam Bioscience is AstraZeneca’s sole Covid vaccine partner in Southeast Asia, a region that is trailing on inoculation and where the virus continues to flare, including in Thailand where infections have surged over the past two months.\nAstraZeneca declined to comment, while Siam BioScience didn’t respond to requests for comment.\nThe Philippines now expects a batch of nearly 1.2 million AstraZeneca shots to be shipped from Thailand in mid-July rather than this month, though a government official saidthe initial delaywill not derail the country’s vaccination push. In Malaysia, authorities say they’re working to resolve the issues around the delivery schedule, which the government stated in May would see 610,000 doses arrive from Thailand in June and another 410,000 in July.\nAstraZeneca itself is also facing legal action from the European Union for a production shortfall, with the company only delivering 30 million doses to the bloc in the first quarter, compared with an original target of 120 million.\nSeeking Alternatives\nThe Anglo-Swedish company, which partnered with the University of Oxford on the vaccine, received orders to supply as many as 3 billion doses worldwide before efficacy data came out last year, more than twice as many as any other first wave shot, data compiled by Bloomberg shows.\nWhile not exclusive to AstraZeneca, the various delays -- particularly out of India, which has banned the export of Covid vaccines -- have left dozens of countries that were counting on the shot desperate to find doses elsewhere, and undermined the company’s bid to supply the developing world.\nNow, countries are turning to alternatives, particularly shots developed by Chinese companies Sinovac and Sinopharm that recently received approval from the WHO. While they’re less effective than the Messenger RNA vaccines made by Pfizer Inc., BioNTech SE and Moderna Inc., these shots are easier to store and transport.\nThailand, which aims to vaccinate70% of its populationby the end of this year, is also now allowing regional health authorities to extend the interval between Astrazeneca vaccine doses to 16 weeks, from 10 to 12 weeks previously, though officials say the move is to optimize the shot’s effectiveness and not for lack of supply.\nThe country has alsoordered20 million doses of the Pfizer-BioNTech vaccine and isin talksfor 5 million doses of the single-shot Johnson & Johnson vaccine as it continues to expect deliveries of the Astra shots from Siam Bioscience.\nNew to Vaccine-making\nAstraZeneca’s vaccine is among the cheapest of the first round of Covid shots because the company said it wouldn’t take a profit, selling it at cost.\nBut the lack of economic incentives could have constrained AstraZeneca and its manufacturing partners’ ability to get the supply chain in order, said Carlos Cordon, a professor of strategy and supply chain management at the Institute for Management Development in Lausanne, Switzerland.\n“The supply chain of the Astra vaccine is not an easy one and, logically, one would assume that there will be more than one source of supply to avoid bottlenecks,” Cordon said. “A little bit of an economic incentive would have certainly helped to make companies in the supply chain even eager to make higher production volumes.”\nAstraZeneca’s choice of Thai partner raised questions from the start. Unlike India’s Serum -- which was the world’s biggest vaccine maker before the pandemic -- and other Asia partners like South Korea’sSK Bioscience Co., Siam Bioscience is new to the vaccine-making business.\nThe company was founded in 2009 as Thailand’s first domestic bio-pharmaceutical drugmaker by the father of the nation’s current King Maha Vajiralongkorn, to provide cheaper alternatives to imported drugs. It has also made Covid test kits.\nIt’s set up by theCrown Property Bureau, an agency that managed assets for the palace no matter who sat on the throne. The company had been operating at a loss in the four years leadingup tothe year of pandemic, when it brought in anet profitof 35.8 million baht ($1.1 million), according to data published by the Department of Business Development.\nIn February, Thai Prime Minister Prayuth Chan-Ocha said Siam Bioscience does not seek to profit from making the Astra vaccines.\nRoyal Links\nComplicating matters is Thailand’s lese majeste law, which can see jail time ofup to15 years for defaming the royal family. Its sweeping mandate means that little is said publicly about Siam Bioscience, even as concerns over vaccine supplies grow.\nIn January, Thai officialssaidthat Siam Bioscience would make 200 million doses each year. They haven’t spoken publicly again about the company in detail since.\nWhen former prime-ministerial candidate Thanathorn Juangroongruangkit suggested that Siam Bioscience’s royal ties played a role in its appointment as AstraZeneca’s partner, the high-profile government critic waschargedwith royal defamation.\nPrime Minister Prayuthapologizedthis week to the public for the delay, blaming “supply and distribution issues” without elaborating. Neither the Thai government nor Siam Bioscience responded to repeated requests for information on what is causing the supply shortfalls.\nOne Thaihealthcareindustry veteran, who asked not to be identified for fear of legal repercussions, likened the situation with Siam Bioscience to a bakery that just started making bread.\n“They still haven’t perfected their craft,” he said. “None of us really knows their production capacity because they haven’t publicized it and we can’t criticize it. No one is willing to say. They can’t say it, because it’s Siam Bioscience.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166595884,"gmtCreate":1624016195848,"gmtModify":1703826615603,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Challenging&nbsp;","listText":"Challenging&nbsp;","text":"Challenging","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166595884","repostId":"2144742013","repostType":4,"repost":{"id":"2144742013","pubTimestamp":1624008600,"share":"https://ttm.financial/m/news/2144742013?lang=&edition=fundamental","pubTime":"2021-06-18 17:30","market":"us","language":"en","title":"Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2144742013","media":"Motley Fool","summary":"The company is generating growth, but its bottom line is cause for some concern.","content":"<p>Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, <b>Tattooed Chef</b> (NASDAQ:TTCF) says in its own investor materials that it's looking to be a disruptive upstart in the fast-growing plant-based foods sector. After a pair of recent acquisitions and a toothsome first-quarter earnings report, investors rewarded the company with a 20% share price increase in May.</p>\n<p>An investor conference began on June 16, allowing investors to get a better look at the company's recent background and get clues as to where it might be going. Here are three points you may want to consider while deciding if Tattooed Chef is the next <b>Beyond Meat</b> (NASDAQ:BYND) or if its weaknesses will limit its growth.</p>\n<h2>1. Tattooed Chef's operations are thriving</h2>\n<p>Despite the company having a traditional advertising budget of zero, Tattooed Chef's sales are booming, with overall revenue jumping 59% year over year from $33.2 million in Q1 2020 to $52.7 million in Q1 2021. An even more favorable sign for customer loyalty and brand recognition was the 105% year-over-year surge in products specifically branded with the Tattooed Chef name (the company also produces store-brand food products for various retailers). The company is projecting between $235 million and $242 million in total revenue for 2021 and a minimum of $300 million in the coming year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9b21e26263590dd121318b21e10d79a\" tg-width=\"700\" tg-height=\"464\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<p>The plant-based food maker is also achieving notable growth in the extent of its distribution network. According to company data, the number of stores carrying its products soared 41% between Dec. 31, 2020, and March 31, 2021, rising from 4,300 to 6,065. Points of distribution jumped to 31,000 from 23,000, an increase of nearly 35%.</p>\n<p>During the Q1 earnings conference call, CEO Salvatore Galletti said that by Q2's end on June 30, \"We expect to be an additional 1,162 stores with 8,000 new points of distribution, including a number of larger grocery chains.\" He added, \"We are confident we can achieve our 2021 objective of 10,000 stores and 65,000 points of distribution for Tattooed Chef by year end.\"</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> early May acquisitions by Tattooed Chef, costing the company a total of $35 million, could be a catalyst for stronger growth and expanded production, too. Tattooed snapped up Karsten Tortilla Factory and New Mexico Food Distributors. According to Galletti, it \"will be immediately addressing the $1 billion Frozen Mexican Food category once the transactions close,\" and will use the new acquisitions as a stepping stone into the $20 billion market for \"Hispanic/Southwest\" food.</p>\n<p>With Abasto reporting around two-thirds of Americans (233 million) using at least some Mexican foods or recipes according to Statista research, and growth in this type of dining expected to continue, Tattooed Chef's move helps it establish a new position in a strong market sector. The purchase also adds 118,000 square feet of production facilities to its total, helping prevent a processing bottleneck during this period of rapid sales growth. Galletti remarks the two acquisitions are projected to \"contribute up to $200 million annually in revenue in the next two to three years and create significant value.\"</p>\n<p>The company is also expanding from a focus on frozen and refrigerated foods to shelf-stable foods (which it refers to with the buzzword phrase \"ambient foods\" in company literature). With sales of major shelf-stable food categories such as vegetables and soups having grown anywhere from 28% to 31.3% in 2020 according to market research firm IRI, this could be another potential sales driver.</p>\n<h2>2. It's not all sunshine for the company</h2>\n<p>Despite its skyrocketing sales and its relative freedom from the expense of a significant advertising budget, Tattooed Chef still registered a net loss in Q1 2021. The company's bottom line has worsened year over year: It produced positive $5.9 million net income in Q1 2020 versus a $7.9 million net loss in the same period this year. It has seen a rise in operating expenses, including a few million directed towards marketing and several million directed towards stock compensation.</p>\n<p>While Tattooed Chef makes plant-based cauliflower burgers, it simply doesn't have the serious research and development (R&amp;D) muscle of Beyond Meat or privately held Impossible Foods to produce meat substitutes at the same level. While Beyond and Impossible maintain laboratories and fund teams of scientists to develop plant protein faux meat closely mimicking the flavor, texture, cooking characteristics, nutrition, and even bleeding of actual meat and are working on similarly advanced plant-based milk and eggs, Tattooed Chef's cauliflower burgers are just spiced and breaded cauliflower patties, a far more casual approach.</p>\n<p>Given that Beyond and Impossible owe their success to the accurate simulation of meat in a plant-based format, Tattooed Chef seems unlikely to tap strongly into that growth market. Its acai bowls, smoothie bowls, and other products, while proving salable, don't have the cutting-edge sales leverage of the advanced faux meats offered by its competitors and might be readily substituted with other companies' frozen meal bowls. Tattooed Chef, at this point, appears to lack the powerful, clear-cut product differentiation at the heart of the success of manufacturers like Beyond Meat.</p>\n<h2>3. The high short interest in Tattooed Chef is a wild card</h2>\n<p>One factor with potentially unpredictable consequences for Tattooed Chef is high short interest, standing at slightly over 36% at the start of June. Under ordinary market conditions, this would be a negative, indicating a large cohort of short-sellers have done their due diligence and found the company's fundamentals to be significantly lacking. A few years ago, this beefy short interest would have been a definitive warning sign about the company's future.</p>\n<p>In today's stock market climate, however, the high short interest could potentially attract the attention of large numbers of retail investors, such as those from the millions-strong r/WallStreetBets Reddit community. Noted for their tremendous short squeeze on the stock of video game seller <b>GameStop</b> and a growing handful of other \"meme stocks,\" these Redditors and other small investors remain on the lookout for heavily shorted stocks to buy in quantity.</p>\n<p>While Tattooed Chef seems to have drawn relatively little notice from these investors up until now, the quest for the next short squeeze takedown could eventually see the company become a meme stock, too. In this case, an attempted squeeze by WallStreetBets readers could pump immense streams of cash into Tattooed Chef, giving the company ample liquidity to aggressively pursue expansion, boost production capacity, and increase the range of product development.</p>\n<h2>Should you add a taste of Tattooed Chef to your portfolio?</h2>\n<p>While Tattooed Chef isn't making the groundbreaking plant-based meat or dairy products of Beyond Meat or Impossible Foods, it appears to have some real potential to become a profitable midsize vegetarian and vegan meal company. Its troubled bottom line and high short interest point to some risk, though, as noted, the latter could become an asset if the company becomes a meme stock and draws a major short squeeze cash inflow from Reddit retail investors at some point.</p>\n<p>Even without such a windfall, however, Tattooed Chef's entry into the Mexican-style food market, along with its rapid development of distribution channels, look like bullish indicators. While the company's future is uncertain and carries some risk, Fools investing in food stocks&nbsp;may want to consider adding at least a few of the company's shares to their holdings.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tattooed Chef the Next Beyond Meat? 3 Points to Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, Tattooed Chef (NASDAQ:TTCF) says in its own investor materials that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PCOM":"Points International","BYND":"Beyond Meat, Inc."},"source_url":"https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144742013","content_text":"Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, Tattooed Chef (NASDAQ:TTCF) says in its own investor materials that it's looking to be a disruptive upstart in the fast-growing plant-based foods sector. After a pair of recent acquisitions and a toothsome first-quarter earnings report, investors rewarded the company with a 20% share price increase in May.\nAn investor conference began on June 16, allowing investors to get a better look at the company's recent background and get clues as to where it might be going. Here are three points you may want to consider while deciding if Tattooed Chef is the next Beyond Meat (NASDAQ:BYND) or if its weaknesses will limit its growth.\n1. Tattooed Chef's operations are thriving\nDespite the company having a traditional advertising budget of zero, Tattooed Chef's sales are booming, with overall revenue jumping 59% year over year from $33.2 million in Q1 2020 to $52.7 million in Q1 2021. An even more favorable sign for customer loyalty and brand recognition was the 105% year-over-year surge in products specifically branded with the Tattooed Chef name (the company also produces store-brand food products for various retailers). The company is projecting between $235 million and $242 million in total revenue for 2021 and a minimum of $300 million in the coming year.\nImage source: Getty Images.\nThe plant-based food maker is also achieving notable growth in the extent of its distribution network. According to company data, the number of stores carrying its products soared 41% between Dec. 31, 2020, and March 31, 2021, rising from 4,300 to 6,065. Points of distribution jumped to 31,000 from 23,000, an increase of nearly 35%.\nDuring the Q1 earnings conference call, CEO Salvatore Galletti said that by Q2's end on June 30, \"We expect to be an additional 1,162 stores with 8,000 new points of distribution, including a number of larger grocery chains.\" He added, \"We are confident we can achieve our 2021 objective of 10,000 stores and 65,000 points of distribution for Tattooed Chef by year end.\"\nTwo early May acquisitions by Tattooed Chef, costing the company a total of $35 million, could be a catalyst for stronger growth and expanded production, too. Tattooed snapped up Karsten Tortilla Factory and New Mexico Food Distributors. According to Galletti, it \"will be immediately addressing the $1 billion Frozen Mexican Food category once the transactions close,\" and will use the new acquisitions as a stepping stone into the $20 billion market for \"Hispanic/Southwest\" food.\nWith Abasto reporting around two-thirds of Americans (233 million) using at least some Mexican foods or recipes according to Statista research, and growth in this type of dining expected to continue, Tattooed Chef's move helps it establish a new position in a strong market sector. The purchase also adds 118,000 square feet of production facilities to its total, helping prevent a processing bottleneck during this period of rapid sales growth. Galletti remarks the two acquisitions are projected to \"contribute up to $200 million annually in revenue in the next two to three years and create significant value.\"\nThe company is also expanding from a focus on frozen and refrigerated foods to shelf-stable foods (which it refers to with the buzzword phrase \"ambient foods\" in company literature). With sales of major shelf-stable food categories such as vegetables and soups having grown anywhere from 28% to 31.3% in 2020 according to market research firm IRI, this could be another potential sales driver.\n2. It's not all sunshine for the company\nDespite its skyrocketing sales and its relative freedom from the expense of a significant advertising budget, Tattooed Chef still registered a net loss in Q1 2021. The company's bottom line has worsened year over year: It produced positive $5.9 million net income in Q1 2020 versus a $7.9 million net loss in the same period this year. It has seen a rise in operating expenses, including a few million directed towards marketing and several million directed towards stock compensation.\nWhile Tattooed Chef makes plant-based cauliflower burgers, it simply doesn't have the serious research and development (R&D) muscle of Beyond Meat or privately held Impossible Foods to produce meat substitutes at the same level. While Beyond and Impossible maintain laboratories and fund teams of scientists to develop plant protein faux meat closely mimicking the flavor, texture, cooking characteristics, nutrition, and even bleeding of actual meat and are working on similarly advanced plant-based milk and eggs, Tattooed Chef's cauliflower burgers are just spiced and breaded cauliflower patties, a far more casual approach.\nGiven that Beyond and Impossible owe their success to the accurate simulation of meat in a plant-based format, Tattooed Chef seems unlikely to tap strongly into that growth market. Its acai bowls, smoothie bowls, and other products, while proving salable, don't have the cutting-edge sales leverage of the advanced faux meats offered by its competitors and might be readily substituted with other companies' frozen meal bowls. Tattooed Chef, at this point, appears to lack the powerful, clear-cut product differentiation at the heart of the success of manufacturers like Beyond Meat.\n3. The high short interest in Tattooed Chef is a wild card\nOne factor with potentially unpredictable consequences for Tattooed Chef is high short interest, standing at slightly over 36% at the start of June. Under ordinary market conditions, this would be a negative, indicating a large cohort of short-sellers have done their due diligence and found the company's fundamentals to be significantly lacking. A few years ago, this beefy short interest would have been a definitive warning sign about the company's future.\nIn today's stock market climate, however, the high short interest could potentially attract the attention of large numbers of retail investors, such as those from the millions-strong r/WallStreetBets Reddit community. Noted for their tremendous short squeeze on the stock of video game seller GameStop and a growing handful of other \"meme stocks,\" these Redditors and other small investors remain on the lookout for heavily shorted stocks to buy in quantity.\nWhile Tattooed Chef seems to have drawn relatively little notice from these investors up until now, the quest for the next short squeeze takedown could eventually see the company become a meme stock, too. In this case, an attempted squeeze by WallStreetBets readers could pump immense streams of cash into Tattooed Chef, giving the company ample liquidity to aggressively pursue expansion, boost production capacity, and increase the range of product development.\nShould you add a taste of Tattooed Chef to your portfolio?\nWhile Tattooed Chef isn't making the groundbreaking plant-based meat or dairy products of Beyond Meat or Impossible Foods, it appears to have some real potential to become a profitable midsize vegetarian and vegan meal company. Its troubled bottom line and high short interest point to some risk, though, as noted, the latter could become an asset if the company becomes a meme stock and draws a major short squeeze cash inflow from Reddit retail investors at some point.\nEven without such a windfall, however, Tattooed Chef's entry into the Mexican-style food market, along with its rapid development of distribution channels, look like bullish indicators. While the company's future is uncertain and carries some risk, Fools investing in food stocks may want to consider adding at least a few of the company's shares to their holdings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166508998,"gmtCreate":1624015316815,"gmtModify":1703826597862,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Good news!","listText":"Good news!","text":"Good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166508998","repostId":"1166489816","repostType":4,"repost":{"id":"1166489816","pubTimestamp":1624009298,"share":"https://ttm.financial/m/news/1166489816?lang=&edition=fundamental","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase&nbsp;2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":120941724,"gmtCreate":1624293588368,"gmtModify":1703832819024,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Nice!&nbsp;","listText":"Nice!&nbsp;","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120941724","repostId":"1154249454","repostType":4,"repost":{"id":"1154249454","pubTimestamp":1624230573,"share":"https://ttm.financial/m/news/1154249454?lang=&edition=fundamental","pubTime":"2021-06-21 07:09","market":"us","language":"en","title":"Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1154249454","media":"barrons","summary":"A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. Wednesday will also feature analyst days and investor events from Johnson & Johnson, GlaxoSmithKline,and Equinix.Economic data out this week include IHS’ Manufacturing and Services Purchasing Managers’ Indexes for June on Wednesday. Both are expected to hold near their record highs. The Census Bureau will r","content":"<p>A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. Wednesday will also feature analyst days and investor events from&nbsp;Johnson &amp;&nbsp;Johnson,&nbsp;GlaxoSmithKline,and&nbsp;Equinix.</p>\n<p>Economic data out this week include IHS’ Manufacturing and Services Purchasing Managers’ Indexes for June on Wednesday. Both are expected to hold near their record highs. The Census Bureau will release the durable-goods report for May on Thursday. Orders—often seen as a decent proxy for business investment—are expected to rise 3.3% month over month.</p>\n<p>And on Friday, the Bureau of Economic Analysis will report personal income and consumption for May. Spending is forecast to continue rising despite a drop off in income as stimulus checks finished being sent out in April.</p>\n<p>Monday 6/21</p>\n<p><b>The Federal Reserve Bank</b>of Chicago releases its National Activity index, a gauge of overall economic activity, for May. Expectations are for a 0.50 reading, higher than April’s 0.24 figure. A positive reading indicates economic growth that is above historical trends.</p>\n<p>Tuesday 6/22</p>\n<p><b>The National Association</b>of Realtors reports existing-home sales for May. Economists forecast a seasonally adjusted annual rate of 5.7 million homes sold, about 150,000 fewer than the April data. Existing-home sales have fallen for three consecutive months, as supply hasn’t been able to keep up with demand.</p>\n<p>Wednesday 6/23</p>\n<p>Equinix hosts its 2021 analyst day, when the company will update its long-term financial outlook.</p>\n<p>GlaxoSmithKline hosts a conference call, featuring its CEO, Emma Walmsley, to update investors on the company’s strategy for growth and shareholder value creation.</p>\n<p>Johnson &amp; Johnson hosts a webcast to discuss its ESG strategy.</p>\n<p><b>The Census Bureau</b>reports new residential construction data for May. Consensus estimate is for a seasonally adjusted annual rate of 875,000 new single-family homes sold, slightly higher than April’s 863,000. Similar to existing-home sales, new-home sales have fallen from their recent peak of 993,000 in January of this year.</p>\n<p><b>IHS Markitreports</b>both its Manufacturing and Services Purchasing Managers’ indexes for June. Expectations are for a 61.5 reading for the Manufacturing PMI, and a 69.8 figure for the Services PMI. Both projections are comparable to the May data as well as being near record highs for their respective indexes.</p>\n<p>Thursday 6/24</p>\n<p><b>The Bureau of Economic Analysis</b>reports the third and final estimate of first-quarter gross-domestic-product growth. Economists forecast a seasonally adjusted annual growth rate of 6.4%.</p>\n<p>Accenture,Darden Restaurants, FedEx, and Nike hold conference calls to discuss quarterly results.</p>\n<p><b>The Bank of England</b>announces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at 0.1%.</p>\n<p><b>The Census Bureau</b>releases the durable-goods report for May. The consensus call is for new orders of manufactured goods to rise 2.8% month over month to $253 billion. Excluding transportation, new orders are projected at 1%, matching the April data.</p>\n<p>Friday 6/25</p>\n<p>CarMax and Paychex report earnings.</p>\n<p><b>The BEA reports</b>personal income and consumption for May. Income is expected to fall 3% month over month, after plummeting 13.1% in April. This reflects a dropoff in stimulus checks that first were sent out in March. Spending is seen rising 0.5%, comparable to the April data.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 07:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/nike-fedex-johnson-johnson-darden-and-other-stocks-for-investors-to-watch-this-week-51624215603?mod=hp_LEAD_3><strong>barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. ...</p>\n\n<a href=\"https://www.barrons.com/articles/nike-fedex-johnson-johnson-darden-and-other-stocks-for-investors-to-watch-this-week-51624215603?mod=hp_LEAD_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","DRI":"达登饭店","FDX":"联邦快递","NKE":"耐克"},"source_url":"https://www.barrons.com/articles/nike-fedex-johnson-johnson-darden-and-other-stocks-for-investors-to-watch-this-week-51624215603?mod=hp_LEAD_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154249454","content_text":"A handful of notable companies will release their latest results toward the end of this week.Nike,FedEx,andDarden Restaurantswill report on Thursday, followed by CarMax and Paychex on Friday. Wednesday will also feature analyst days and investor events from Johnson & Johnson, GlaxoSmithKline,and Equinix.\nEconomic data out this week include IHS’ Manufacturing and Services Purchasing Managers’ Indexes for June on Wednesday. Both are expected to hold near their record highs. The Census Bureau will release the durable-goods report for May on Thursday. Orders—often seen as a decent proxy for business investment—are expected to rise 3.3% month over month.\nAnd on Friday, the Bureau of Economic Analysis will report personal income and consumption for May. Spending is forecast to continue rising despite a drop off in income as stimulus checks finished being sent out in April.\nMonday 6/21\nThe Federal Reserve Bankof Chicago releases its National Activity index, a gauge of overall economic activity, for May. Expectations are for a 0.50 reading, higher than April’s 0.24 figure. A positive reading indicates economic growth that is above historical trends.\nTuesday 6/22\nThe National Associationof Realtors reports existing-home sales for May. Economists forecast a seasonally adjusted annual rate of 5.7 million homes sold, about 150,000 fewer than the April data. Existing-home sales have fallen for three consecutive months, as supply hasn’t been able to keep up with demand.\nWednesday 6/23\nEquinix hosts its 2021 analyst day, when the company will update its long-term financial outlook.\nGlaxoSmithKline hosts a conference call, featuring its CEO, Emma Walmsley, to update investors on the company’s strategy for growth and shareholder value creation.\nJohnson & Johnson hosts a webcast to discuss its ESG strategy.\nThe Census Bureaureports new residential construction data for May. Consensus estimate is for a seasonally adjusted annual rate of 875,000 new single-family homes sold, slightly higher than April’s 863,000. Similar to existing-home sales, new-home sales have fallen from their recent peak of 993,000 in January of this year.\nIHS Markitreportsboth its Manufacturing and Services Purchasing Managers’ indexes for June. Expectations are for a 61.5 reading for the Manufacturing PMI, and a 69.8 figure for the Services PMI. Both projections are comparable to the May data as well as being near record highs for their respective indexes.\nThursday 6/24\nThe Bureau of Economic Analysisreports the third and final estimate of first-quarter gross-domestic-product growth. Economists forecast a seasonally adjusted annual growth rate of 6.4%.\nAccenture,Darden Restaurants, FedEx, and Nike hold conference calls to discuss quarterly results.\nThe Bank of Englandannounces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at 0.1%.\nThe Census Bureaureleases the durable-goods report for May. The consensus call is for new orders of manufactured goods to rise 2.8% month over month to $253 billion. Excluding transportation, new orders are projected at 1%, matching the April data.\nFriday 6/25\nCarMax and Paychex report earnings.\nThe BEA reportspersonal income and consumption for May. Income is expected to fall 3% month over month, after plummeting 13.1% in April. This reflects a dropoff in stimulus checks that first were sent out in March. Spending is seen rising 0.5%, comparable to the April data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166595884,"gmtCreate":1624016195848,"gmtModify":1703826615603,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Challenging&nbsp;","listText":"Challenging&nbsp;","text":"Challenging","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166595884","repostId":"2144742013","repostType":4,"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121284124,"gmtCreate":1624465646268,"gmtModify":1703837707980,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121284124","repostId":"1145825451","repostType":4,"repost":{"id":"1145825451","pubTimestamp":1624433586,"share":"https://ttm.financial/m/news/1145825451?lang=&edition=fundamental","pubTime":"2021-06-23 15:33","market":"us","language":"en","title":"Why I Believe NIO Will Beat Out Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=1145825451","media":"InvestorPlace","summary":"The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.Super fans of the latest and greatest high-endTesla, Inc. model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.The go","content":"<blockquote>\n <b>The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.</b>\n</blockquote>\n<p>Super fans of the latest and greatest high-end<b>Tesla, Inc.</b>(NASDAQ:<b>TSLA</b>) model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.</p>\n<p><img src=\"https://static.tigerbbs.com/b294a3604c7ba82bd19b3c70be3a4020\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: nrqemi / Shutterstock.com</p>\n<p>Musk wrote there was… “No need, as Plaid is just so good.”</p>\n<p>The Model S Plaid Plus was supposed to be the fastest, most powerful and priciest version of the company’s Model S. Priced at $149,990, it was to feature a range of 520 miles, thanks to its innovative 4680 battery cells, 1,100 horsepower and the ability to speed from 0 to 60 mph in less than two seconds.</p>\n<p>Instead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.</p>\n<p>As a way to “sugar coat” its flip flop, Tesla said the Model S Plaid is just as fast as the Model S Plaid Plus and $20,000 cheaper. Humm.</p>\n<p>This “bait and switch” has some Tesla fans worried, since they had deposits on the Model S Plaid Plus and wanted the innovative 4680 battery cells that Tesla had been touting as the key to longer range and more power. Essentially, the 4680 battery cells were the latest great Tesla development, since they were the first batteries to also be a structural component that supposedly allowed Tesla to lower the weight of its vehicles.</p>\n<p>Both the company’s Austin and Berlin manufacturing plants now under construction are supposed to also be making the 4680 batteries for new Tesla vehicles. If there is a problem with the engineering associated with utilizing the 4680 batteries or making them a structural component, then Tesla has grossly miscalculated, which is now worrying investors.</p>\n<p>Clearly something happened to delay the 4680 batteries that were supposed to provide Tesla with a competitive and engineering edge. For Tesla’s sake, I hope they figure out the problems associated with their much hyped 4680 battery cells, otherwise concerns about its two new manufacturing plants will emerge, as well as the stock losing more of its “mojo.”</p>\n<p>As someone who owns more than a few high-performance vehicles, I can tell you that the engineering geeks I know do<i>not</i>want to get a new Model S Plaid instead of a Model S Plaid Plus and will likely ask for their deposits back.</p>\n<p>What Tesla did is like Ferrari or Porsche telling its customers that one of their much-hyped new performance models is now not being sold because the base model was just as good! Car fanatics, like myself, like the latest and greatest engineering tidbits, so we would rather cancel our orders versus settle for a base model.</p>\n<p>The good news for Tesla is that its China sales in May resurged to 21,936, up sharply from 11,671 in April. The company’s sales tend to spike at the end of each quarter. For example, Tesla sold 35,478 vehicles in China in March, which was the strongest month ever in China.</p>\n<p>This is raising expectations for very strong China sales in June, especially now that the Model Y is being manufactured in Shanghai. Interestingly, since most Chinese Teslas are now made with iron phosphate batteries, these vehicles have lower range than its lithium cobalt vehicles, but its iron phosphate vehicles are cheaper and now increasingly being exported to Europe.</p>\n<p>However, I’m convinced another electric vehicle (EV) company will eventually displace Tesla as the biggest manufacturer of EVs in China.</p>\n<p><b>Taking Advantage of the EV Revolution’s Profit Potential</b></p>\n<p>I’m talking about&nbsp;<b>Nio, Inc.</b>(NYSE:<b>NIO</b>). The reality is that this company is on the verge of dominating the EV market in China and Hong Kong. It’s why I put NIO on my<b><i>Platinum Growth Club</i></b>Model Portfolio back in February.</p>\n<p>The company boasts that it is the “next-generation car company,” as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence (AI). NIO currently offers an electric seven-seater SUV (ES8) and a five-seater electric SUV (ES6) and recently introduced an attractive electric sedan (ET7). Its vehicles utilize NOMI, an in-vehicle artificial intelligence assistant.</p>\n<p>The company is also partnering with cutting-edge chip companies like<b>NVIDIA Corporation</b>(NASDAQ:<b>NVDA</b>), another one of my<b><i>Platinum Growth Club</i></b>Model Portfolio stocks. NIO plans to use the NVIDIA DRIVE Orin system-on-a-chip for its electric vehicles that will provide autonomous driving capabilities. The NVIDIA DRIVE Orin-powered supercomputer, which is being called Adam, will be launched in the ET7 sedan in China in 2022. Announcements like this are very positive, so NIO has been stealing some of Tesla’s thunder lately.</p>\n<p>Now, it’s important to note that NIO was bailed out by the Chinese government. Last year, the Chinese government injected $1 billion and now has a 24% ownership in the company. The reality is that China wants to dominate at least five major industries by 2025, and NIO is now its ticket to dominate EV manufacturing.</p>\n<p>With the backing of the Chinese government, some Wall Street firms are eager to help NIO by issuing new debt or equity. So, I wouldn’t be surprised if NIO surpasses Tesla, which is currently number-two in China, for market share in the upcoming years.</p>\n<p>That means, if you missed Tesla’s parabolic run like I did, NIO is essentially giving us a “second chance” to make money in a potentially explosive electric vehicle company.</p>\n<p>Shares of NIO climbed nearly 13% since the company’s June 4 announcement of its May delivery report and positive analyst comments, while Tesla shares rose almost 3%. First, NIO revealed that the global chip shortage is starting to take a toll on its business. NIO only delivered 6,711 vehicles in May, or a 5.5% decline from April’s deliveries. Company management noted that deliveries were “adversely impacted for several days due to the volatility of semiconductor supply and certain logistical adjustments.”</p>\n<p>Interestingly, despite the month-to-month dip, NIO’s deliveries were still up 95.3% year-over-year. Strong demand in China even inspired a Citigroup analyst to upgrade NIO to a buy rating, as he expects demand to accelerate in the coming months.</p>\n<p>In other words, NIO represents the<b>crème de la crème</b>of EV stocks right now.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why I Believe NIO Will Beat Out Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy I Believe NIO Will Beat Out Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 15:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.\n\nSuper fans of the latest and greatest high-endTesla, Inc.(NASDAQ:TSLA) model received some disappointing news a week ...</p>\n\n<a href=\"https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/06/why-i-believe-nio-will-beat-out-tesla/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145825451","content_text":"The fact that Tesla scrapped its Model S Plaid Plus release is just part of it.\n\nSuper fans of the latest and greatest high-endTesla, Inc.(NASDAQ:TSLA) model received some disappointing news a week ago when CEO Elon Musk abruptly canceled the release of its highly anticipated Model S Plaid Plus with a tweet on June 6.\nSource: nrqemi / Shutterstock.com\nMusk wrote there was… “No need, as Plaid is just so good.”\nThe Model S Plaid Plus was supposed to be the fastest, most powerful and priciest version of the company’s Model S. Priced at $149,990, it was to feature a range of 520 miles, thanks to its innovative 4680 battery cells, 1,100 horsepower and the ability to speed from 0 to 60 mph in less than two seconds.\nInstead, the company has begun delivering a new Model S Plaid that has only a 390-mile range and 1,020 horsepower, though it still sprints to from 0 to 60 miles per hour in just two seconds.\nAs a way to “sugar coat” its flip flop, Tesla said the Model S Plaid is just as fast as the Model S Plaid Plus and $20,000 cheaper. Humm.\nThis “bait and switch” has some Tesla fans worried, since they had deposits on the Model S Plaid Plus and wanted the innovative 4680 battery cells that Tesla had been touting as the key to longer range and more power. Essentially, the 4680 battery cells were the latest great Tesla development, since they were the first batteries to also be a structural component that supposedly allowed Tesla to lower the weight of its vehicles.\nBoth the company’s Austin and Berlin manufacturing plants now under construction are supposed to also be making the 4680 batteries for new Tesla vehicles. If there is a problem with the engineering associated with utilizing the 4680 batteries or making them a structural component, then Tesla has grossly miscalculated, which is now worrying investors.\nClearly something happened to delay the 4680 batteries that were supposed to provide Tesla with a competitive and engineering edge. For Tesla’s sake, I hope they figure out the problems associated with their much hyped 4680 battery cells, otherwise concerns about its two new manufacturing plants will emerge, as well as the stock losing more of its “mojo.”\nAs someone who owns more than a few high-performance vehicles, I can tell you that the engineering geeks I know donotwant to get a new Model S Plaid instead of a Model S Plaid Plus and will likely ask for their deposits back.\nWhat Tesla did is like Ferrari or Porsche telling its customers that one of their much-hyped new performance models is now not being sold because the base model was just as good! Car fanatics, like myself, like the latest and greatest engineering tidbits, so we would rather cancel our orders versus settle for a base model.\nThe good news for Tesla is that its China sales in May resurged to 21,936, up sharply from 11,671 in April. The company’s sales tend to spike at the end of each quarter. For example, Tesla sold 35,478 vehicles in China in March, which was the strongest month ever in China.\nThis is raising expectations for very strong China sales in June, especially now that the Model Y is being manufactured in Shanghai. Interestingly, since most Chinese Teslas are now made with iron phosphate batteries, these vehicles have lower range than its lithium cobalt vehicles, but its iron phosphate vehicles are cheaper and now increasingly being exported to Europe.\nHowever, I’m convinced another electric vehicle (EV) company will eventually displace Tesla as the biggest manufacturer of EVs in China.\nTaking Advantage of the EV Revolution’s Profit Potential\nI’m talking about Nio, Inc.(NYSE:NIO). The reality is that this company is on the verge of dominating the EV market in China and Hong Kong. It’s why I put NIO on myPlatinum Growth ClubModel Portfolio back in February.\nThe company boasts that it is the “next-generation car company,” as it designs and manufactures electric vehicles that utilize the latest technologies in connectivity, autonomous driving and artificial intelligence (AI). NIO currently offers an electric seven-seater SUV (ES8) and a five-seater electric SUV (ES6) and recently introduced an attractive electric sedan (ET7). Its vehicles utilize NOMI, an in-vehicle artificial intelligence assistant.\nThe company is also partnering with cutting-edge chip companies likeNVIDIA Corporation(NASDAQ:NVDA), another one of myPlatinum Growth ClubModel Portfolio stocks. NIO plans to use the NVIDIA DRIVE Orin system-on-a-chip for its electric vehicles that will provide autonomous driving capabilities. The NVIDIA DRIVE Orin-powered supercomputer, which is being called Adam, will be launched in the ET7 sedan in China in 2022. Announcements like this are very positive, so NIO has been stealing some of Tesla’s thunder lately.\nNow, it’s important to note that NIO was bailed out by the Chinese government. Last year, the Chinese government injected $1 billion and now has a 24% ownership in the company. The reality is that China wants to dominate at least five major industries by 2025, and NIO is now its ticket to dominate EV manufacturing.\nWith the backing of the Chinese government, some Wall Street firms are eager to help NIO by issuing new debt or equity. So, I wouldn’t be surprised if NIO surpasses Tesla, which is currently number-two in China, for market share in the upcoming years.\nThat means, if you missed Tesla’s parabolic run like I did, NIO is essentially giving us a “second chance” to make money in a potentially explosive electric vehicle company.\nShares of NIO climbed nearly 13% since the company’s June 4 announcement of its May delivery report and positive analyst comments, while Tesla shares rose almost 3%. First, NIO revealed that the global chip shortage is starting to take a toll on its business. NIO only delivered 6,711 vehicles in May, or a 5.5% decline from April’s deliveries. Company management noted that deliveries were “adversely impacted for several days due to the volatility of semiconductor supply and certain logistical adjustments.”\nInterestingly, despite the month-to-month dip, NIO’s deliveries were still up 95.3% year-over-year. Strong demand in China even inspired a Citigroup analyst to upgrade NIO to a buy rating, as he expects demand to accelerate in the coming months.\nIn other words, NIO represents thecrème de la crèmeof EV stocks right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123850779,"gmtCreate":1624417021291,"gmtModify":1703836042030,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123850779","repostId":"1125623159","repostType":4,"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162946122,"gmtCreate":1624032709066,"gmtModify":1703827277258,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162946122","repostId":"1192473918","repostType":4,"repost":{"id":"1192473918","pubTimestamp":1624029343,"share":"https://ttm.financial/m/news/1192473918?lang=&edition=fundamental","pubTime":"2021-06-18 23:15","market":"us","language":"en","title":"PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1192473918","media":"investorplace","summary":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Feder","content":"<p><b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).</p>\n<p>The goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.</p>\n<p>According to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.</p>\n<p>Palantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.</p>\n<p>Akash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.</p>\n<blockquote>\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n</blockquote>\n<p>The fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.</p>\n<p>It’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.</p>\n<p>PLTR stock was down 1.1% as of Friday morning.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” ...</p>\n\n<a href=\"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192473918","content_text":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.\nAccording to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.\nPalantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.\nAkash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.\n\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n\nThe fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.\nIt’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.\nPLTR stock was down 1.1% as of Friday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162943055,"gmtCreate":1624032632377,"gmtModify":1703827272399,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162943055","repostId":"2144774740","repostType":4,"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166508998,"gmtCreate":1624015316815,"gmtModify":1703826597862,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Good news!","listText":"Good news!","text":"Good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166508998","repostId":"1166489816","repostType":4,"repost":{"id":"1166489816","pubTimestamp":1624009298,"share":"https://ttm.financial/m/news/1166489816?lang=&edition=fundamental","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase&nbsp;2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126856071,"gmtCreate":1624552429193,"gmtModify":1703840297325,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Never ending of sales&nbsp;","listText":"Never ending of sales&nbsp;","text":"Never ending of sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126856071","repostId":"1120836318","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166530663,"gmtCreate":1624016385152,"gmtModify":1703826618839,"author":{"id":"3578295543603682","authorId":"3578295543603682","authorIdStr":"3578295543603682","name":"jying96","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578295543603682"},"themes":[],"htmlText":"Oh no…","listText":"Oh no…","text":"Oh no…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166530663","repostId":"1176081814","repostType":4,"repost":{"id":"1176081814","pubTimestamp":1624002595,"share":"https://ttm.financial/m/news/1176081814?lang=&edition=fundamental","pubTime":"2021-06-18 15:49","market":"us","language":"en","title":"AstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=1176081814","media":"bloomberg","summary":"AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery tar","content":"<p>AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback for a shot that was meant to be the backbone of the global inoculation effort.</p>\n<p>Thailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only about 3.5 million of those shots this month. Pledging to still give out 6 million doses as planned, officials appear to be making up the shortfall with millions of shots from China’sSinovac Biotech Ltd.</p>\n<p>Shipments of shots made by Siam Bioscience -- AstraZeneca’s Bangkok-based partner, which has links to the Thai royal family -- to Malaysia and the Philippines have also been delayed, though both countries say they don’t expect to be waiting for too long.</p>\n<p>The situation comes on top of delivery problems at India’sSerum Institute of India Ltd., another AstraZeneca partner, which has left developing countries from Nepal to Rwanda short of shots that were promised through the World Health Organization-backed Covax program. Siam Bioscience is AstraZeneca’s sole Covid vaccine partner in Southeast Asia, a region that is trailing on inoculation and where the virus continues to flare, including in Thailand where infections have surged over the past two months.</p>\n<p>AstraZeneca declined to comment, while Siam BioScience didn’t respond to requests for comment.</p>\n<p>The Philippines now expects a batch of nearly 1.2 million AstraZeneca shots to be shipped from Thailand in mid-July rather than this month, though a government official saidthe initial delaywill not derail the country’s vaccination push. In Malaysia, authorities say they’re working to resolve the issues around the delivery schedule, which the government stated in May would see 610,000 doses arrive from Thailand in June and another 410,000 in July.</p>\n<p>AstraZeneca itself is also facing legal action from the European Union for a production shortfall, with the company only delivering 30 million doses to the bloc in the first quarter, compared with an original target of 120 million.</p>\n<p>Seeking Alternatives</p>\n<p>The Anglo-Swedish company, which partnered with the University of Oxford on the vaccine, received orders to supply as many as 3 billion doses worldwide before efficacy data came out last year, more than twice as many as any other first wave shot, data compiled by Bloomberg shows.</p>\n<p>While not exclusive to AstraZeneca, the various delays -- particularly out of India, which has banned the export of Covid vaccines -- have left dozens of countries that were counting on the shot desperate to find doses elsewhere, and undermined the company’s bid to supply the developing world.</p>\n<p>Now, countries are turning to alternatives, particularly shots developed by Chinese companies Sinovac and Sinopharm that recently received approval from the WHO. While they’re less effective than the Messenger RNA vaccines made by Pfizer Inc., BioNTech SE and Moderna Inc., these shots are easier to store and transport.</p>\n<p>Thailand, which aims to vaccinate70% of its populationby the end of this year, is also now allowing regional health authorities to extend the interval between Astrazeneca vaccine doses to 16 weeks, from 10 to 12 weeks previously, though officials say the move is to optimize the shot’s effectiveness and not for lack of supply.</p>\n<p>The country has alsoordered20 million doses of the Pfizer-BioNTech vaccine and isin talksfor 5 million doses of the single-shot Johnson &amp; Johnson vaccine as it continues to expect deliveries of the Astra shots from Siam Bioscience.</p>\n<p>New to Vaccine-making</p>\n<p>AstraZeneca’s vaccine is among the cheapest of the first round of Covid shots because the company said it wouldn’t take a profit, selling it at cost.</p>\n<p>But the lack of economic incentives could have constrained AstraZeneca and its manufacturing partners’ ability to get the supply chain in order, said Carlos Cordon, a professor of strategy and supply chain management at the Institute for Management Development in Lausanne, Switzerland.</p>\n<p>“The supply chain of the Astra vaccine is not an easy one and, logically, one would assume that there will be more than one source of supply to avoid bottlenecks,” Cordon said. “A little bit of an economic incentive would have certainly helped to make companies in the supply chain even eager to make higher production volumes.”</p>\n<p>AstraZeneca’s choice of Thai partner raised questions from the start. Unlike India’s Serum -- which was the world’s biggest vaccine maker before the pandemic -- and other Asia partners like South Korea’sSK Bioscience Co., Siam Bioscience is new to the vaccine-making business.</p>\n<p>The company was founded in 2009 as Thailand’s first domestic bio-pharmaceutical drugmaker by the father of the nation’s current King Maha Vajiralongkorn, to provide cheaper alternatives to imported drugs. It has also made Covid test kits.</p>\n<p>It’s set up by theCrown Property Bureau, an agency that managed assets for the palace no matter who sat on the throne. The company had been operating at a loss in the four years leadingup tothe year of pandemic, when it brought in anet profitof 35.8 million baht ($1.1 million), according to data published by the Department of Business Development.</p>\n<p>In February, Thai Prime Minister Prayuth Chan-Ocha said Siam Bioscience does not seek to profit from making the Astra vaccines.</p>\n<p>Royal Links</p>\n<p>Complicating matters is Thailand’s lese majeste law, which can see jail time ofup to15 years for defaming the royal family. Its sweeping mandate means that little is said publicly about Siam Bioscience, even as concerns over vaccine supplies grow.</p>\n<p>In January, Thai officialssaidthat Siam Bioscience would make 200 million doses each year. They haven’t spoken publicly again about the company in detail since.</p>\n<p>When former prime-ministerial candidate Thanathorn Juangroongruangkit suggested that Siam Bioscience’s royal ties played a role in its appointment as AstraZeneca’s partner, the high-profile government critic waschargedwith royal defamation.</p>\n<p>Prime Minister Prayuthapologizedthis week to the public for the delay, blaming “supply and distribution issues” without elaborating. Neither the Thai government nor Siam Bioscience responded to repeated requests for information on what is causing the supply shortfalls.</p>\n<p>One Thaihealthcareindustry veteran, who asked not to be identified for fear of legal repercussions, likened the situation with Siam Bioscience to a bakery that just started making bread.</p>\n<p>“They still haven’t perfected their craft,” he said. “None of us really knows their production capacity because they haven’t publicized it and we can’t criticize it. No one is willing to say. They can’t say it, because it’s Siam Bioscience.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Vaccine Faces More Supply Hurdles, Now From Thailand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 15:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-18/astrazeneca-vaccine-faces-more-supply-hurdles-now-from-thailand?srnd=premium-asia><strong>bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-18/astrazeneca-vaccine-faces-more-supply-hurdles-now-from-thailand?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-18/astrazeneca-vaccine-faces-more-supply-hurdles-now-from-thailand?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176081814","content_text":"AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback for a shot that was meant to be the backbone of the global inoculation effort.\nThailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only about 3.5 million of those shots this month. Pledging to still give out 6 million doses as planned, officials appear to be making up the shortfall with millions of shots from China’sSinovac Biotech Ltd.\nShipments of shots made by Siam Bioscience -- AstraZeneca’s Bangkok-based partner, which has links to the Thai royal family -- to Malaysia and the Philippines have also been delayed, though both countries say they don’t expect to be waiting for too long.\nThe situation comes on top of delivery problems at India’sSerum Institute of India Ltd., another AstraZeneca partner, which has left developing countries from Nepal to Rwanda short of shots that were promised through the World Health Organization-backed Covax program. Siam Bioscience is AstraZeneca’s sole Covid vaccine partner in Southeast Asia, a region that is trailing on inoculation and where the virus continues to flare, including in Thailand where infections have surged over the past two months.\nAstraZeneca declined to comment, while Siam BioScience didn’t respond to requests for comment.\nThe Philippines now expects a batch of nearly 1.2 million AstraZeneca shots to be shipped from Thailand in mid-July rather than this month, though a government official saidthe initial delaywill not derail the country’s vaccination push. In Malaysia, authorities say they’re working to resolve the issues around the delivery schedule, which the government stated in May would see 610,000 doses arrive from Thailand in June and another 410,000 in July.\nAstraZeneca itself is also facing legal action from the European Union for a production shortfall, with the company only delivering 30 million doses to the bloc in the first quarter, compared with an original target of 120 million.\nSeeking Alternatives\nThe Anglo-Swedish company, which partnered with the University of Oxford on the vaccine, received orders to supply as many as 3 billion doses worldwide before efficacy data came out last year, more than twice as many as any other first wave shot, data compiled by Bloomberg shows.\nWhile not exclusive to AstraZeneca, the various delays -- particularly out of India, which has banned the export of Covid vaccines -- have left dozens of countries that were counting on the shot desperate to find doses elsewhere, and undermined the company’s bid to supply the developing world.\nNow, countries are turning to alternatives, particularly shots developed by Chinese companies Sinovac and Sinopharm that recently received approval from the WHO. While they’re less effective than the Messenger RNA vaccines made by Pfizer Inc., BioNTech SE and Moderna Inc., these shots are easier to store and transport.\nThailand, which aims to vaccinate70% of its populationby the end of this year, is also now allowing regional health authorities to extend the interval between Astrazeneca vaccine doses to 16 weeks, from 10 to 12 weeks previously, though officials say the move is to optimize the shot’s effectiveness and not for lack of supply.\nThe country has alsoordered20 million doses of the Pfizer-BioNTech vaccine and isin talksfor 5 million doses of the single-shot Johnson & Johnson vaccine as it continues to expect deliveries of the Astra shots from Siam Bioscience.\nNew to Vaccine-making\nAstraZeneca’s vaccine is among the cheapest of the first round of Covid shots because the company said it wouldn’t take a profit, selling it at cost.\nBut the lack of economic incentives could have constrained AstraZeneca and its manufacturing partners’ ability to get the supply chain in order, said Carlos Cordon, a professor of strategy and supply chain management at the Institute for Management Development in Lausanne, Switzerland.\n“The supply chain of the Astra vaccine is not an easy one and, logically, one would assume that there will be more than one source of supply to avoid bottlenecks,” Cordon said. “A little bit of an economic incentive would have certainly helped to make companies in the supply chain even eager to make higher production volumes.”\nAstraZeneca’s choice of Thai partner raised questions from the start. Unlike India’s Serum -- which was the world’s biggest vaccine maker before the pandemic -- and other Asia partners like South Korea’sSK Bioscience Co., Siam Bioscience is new to the vaccine-making business.\nThe company was founded in 2009 as Thailand’s first domestic bio-pharmaceutical drugmaker by the father of the nation’s current King Maha Vajiralongkorn, to provide cheaper alternatives to imported drugs. It has also made Covid test kits.\nIt’s set up by theCrown Property Bureau, an agency that managed assets for the palace no matter who sat on the throne. The company had been operating at a loss in the four years leadingup tothe year of pandemic, when it brought in anet profitof 35.8 million baht ($1.1 million), according to data published by the Department of Business Development.\nIn February, Thai Prime Minister Prayuth Chan-Ocha said Siam Bioscience does not seek to profit from making the Astra vaccines.\nRoyal Links\nComplicating matters is Thailand’s lese majeste law, which can see jail time ofup to15 years for defaming the royal family. Its sweeping mandate means that little is said publicly about Siam Bioscience, even as concerns over vaccine supplies grow.\nIn January, Thai officialssaidthat Siam Bioscience would make 200 million doses each year. They haven’t spoken publicly again about the company in detail since.\nWhen former prime-ministerial candidate Thanathorn Juangroongruangkit suggested that Siam Bioscience’s royal ties played a role in its appointment as AstraZeneca’s partner, the high-profile government critic waschargedwith royal defamation.\nPrime Minister Prayuthapologizedthis week to the public for the delay, blaming “supply and distribution issues” without elaborating. Neither the Thai government nor Siam Bioscience responded to repeated requests for information on what is causing the supply shortfalls.\nOne Thaihealthcareindustry veteran, who asked not to be identified for fear of legal repercussions, likened the situation with Siam Bioscience to a bakery that just started making bread.\n“They still haven’t perfected their craft,” he said. “None of us really knows their production capacity because they haven’t publicized it and we can’t criticize it. No one is willing to say. They can’t say it, because it’s Siam Bioscience.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}